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ABSTRACT  
   
The communication of genetic material with biomolecules has been a major 
interest in cancer biology research for decades. Among its different levels of 
involvement, DNA is known to be a target of several antitumor agents. Additionally, 
tissue specific interaction between macromolecules such as proteins and structurally 
important regions of DNA has been reported to define the onset of certain types of 
cancers.  
 Illustrated in Chapter 1 is the general history of research on the interaction of 
DNA and anticancer drugs, most importantly different congener of bleomycin (BLM). 
Additionally, several synthetic analogues of bleomycin, including the structural 
components and functionalities, are discussed.  
 Chapter 2 describes a new approach to study the double-strand DNA lesion 
caused by antitumor drug bleomycin. The hairpin DNA library used in this study displays 
numerous cleavage sites demonstrating the versatility of bleomycin interaction with 
DNA. Interestingly, some of those cleavage sites suggest a novel mechanism of 
bleomycin interaction, which has not been reported before.  
 Cytidine methylation has generally been found to decrease site-specific cleavage 
of DNA by BLM, possibly due to structural change and subsequent reduced bleomycin-
mediated recognition of DNA. As illustrated in Chapter 3, three hairpin DNAs known to 
be strongly bound by bleomycin, and their methylated counterparts, were used to study 
the dynamics of bleomycin-induced degradation of DNAs in cancer cells. Interestingly, 
cytidine methylation on one of the DNAs has also shown a major shift in the intensity of 
 ii 
bleomycin induced double-strand DNA cleavage pattern, which is known to be a more 
potent form of bleomycin induced cleavages.  
 DNA secondary structures are known to play important roles in gene regulation. 
Chapter 4 demonstrates a structural change of the BCL2 promoter element as a result of 
its dynamic interaction with the individual domains of hnRNP LL, which is essential to 
facilitate the transcription of BCL2. Furthermore, an in vitro protein synthesis technique 
has been employed to study the dynamic interaction between protein domains and the i-
motif DNA within the promoter element. Several constructs were made involving 
replacement of a single amino acid with a fluorescent analogue, and these were used to 
study FRET between domain 1 and the i-motif, the later of which harbored a fluorescent 
acceptor nucleotide analogue.  
 iii 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1. Molecular Therapeutics of Cancer Research 
Cancer is an uncontrolled growth of normal cells in the body. It claims millions of 
lives worldwide every year and it is a major public health concern.1 Symptoms of cancer 
involve abnormal cell growth, bleeding, cough, and weight loss.2 Among several types of 
cancers, lung and prostate cancers are most common in men, whereas breast, cervical and 
ovarian cancers are prevalent in females.3 Leukemia, brain tumors and skin cancers are 
other types of cancer that affect a wide population of all ages.4 Increased risk of cancer is 
associated with developing countries5 and with age,6 though it has been argued that the 
increased life expectancy has contributed to the higher occurrence of cancer in developed 
countries. Although the majority of cancers most likely develop due to environmental 
causes,7 genetics8 and lifestyle also play an important role in the development of 
malignancies. Other factors include smoking,9,10 diet, infection, exposure to radiation and 
stress.11 The treatment of cancer is practiced at several different levels, including 
chemotherapy, radiation therapy, hormonal treatment and patient counseling. 
Chemotherapy research broadly involves the synthesis and study of novel 
chemotherapeutic agents for the diagnosis and treatment of cancer. Therapeutic 
anticancer agents are mainly designed with a curative intent to prolong life. DNA-
targeted agents constitute a broad class of therapeutic anticancer agents and can be 
classified into sub-categories such as, intercalators and groove binders (Figure 1.1). 
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Figure 1.1. Groove Binding of Hoescht 33258 to the Minor Groove of DNA (A, NDB 
Structure   8bna)12 and the Intercalation of Ellipticine into DNA (B, NDB Structure 
1z3f).13  
 
 
 DNA intercalation involves insertion of a planar molecule in between base pairs, 
which results in helix unwinding while groove binders are mainly crescent-shaped 
molecules, which interact with the minor groove of DNA. Without inducing large 
conformational changes in DNA, these groove binders have higher association energy 
than intercalators and they are of high clinical utility as therapeutic antitumor agents.14 
Some of the classical DNA intercalators and groove binders are listed in Figure 1.2. 
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Figure 1.2. Structures of Typical Intercalators, Atypical Intercalators, and Groove 
Binders.15 
 
 
1.2. Bleomycin and DNA 
Bleomycins are a class of DNA minor groove binding or intercalative 
glycopeptide antibiotics, known for their antitumor activity. The cytotoxicity of 
bleomycin is believed to result from sequence-selective oxidative cleavage of DNA16,17 
and RNA,18 in the presence of oxygen and metal ion cofactors. In nature, bleomycin is 
produced by Streptomyces verticillus. In 1966, Umezawa and co-workers extracted 
bleomycin from S. verticillus in the copper-chelated form, and extensively studied its 
antimicrobial activity.19,20 The drug was marketed in Japan  by Nippon Kayaku in 1969. 
In July 1973, bleomycin gained FDA approval and was marketed as an antitumor agent 
by Bristol Laboratories, under the trade name Blenoxane. Currently, in the United States 
the drug is being used in combination with other antitumor agents. The main components 
of Blenoxane are different congeners of bleomycin, primarily BLM A2 (~60%) and BLM 
B2 (~30%) (Figure 1.3). In other parts of the world, bleomycin A5 (pingyangmycin) is 
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more widely used. In China, bleomycin A5 has largely replaced bleomycin A2 because of 
its relatively low cost of production and it is used for the treatment of a larger variety of 
cancers including breast and liver.21-23 Pingyangmycin (bleomycin A5) is also known for 
causing less damage to the lungs during chemotherapy, although prolonged treatment can 
cause pulmonary fibrosis. Unlike the other variants of bleomycin, BLM A5 can trigger 
anaphylactic shock and can be fatal even at low dosage.24    
 
 
Figure 1.3. Different Congeners of Bleomycin. 
 
The tumor cell killing effect of bleomycin has been largely attributed to oxygen 
mediated DNA cleavage by bleomycin. Therefore oxygen rich pulmonary tissues are 
believed to be more susceptible to bleomycin induced damage. A different hypothesis 
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states that the polyamide side chains of bleomycin are the reason of toxicity in lung 
tissues. Similar phenomena are also observed with other structurally similar glycopeptide 
antibiotics, such as phleomycin, zorbamycin and tallysomycin (Figure 1.4).25-27 
 
 
 
Figure 1.4. Structural Compositions of Antitumor Antibiotics Bleomycin A2, B2, 
Tallysomycin S10B, Phleomycin D1 and Zorbamycin.
26 
 
 
1.3. Strustural Domains of Bleomycin 
The total synthesis of bleomycin was achieved in the Hecht28 and Umezawa29 
laboratories in 1982 and in the Boger laboratory30 in 1994 followed by the successful 
synthesis of a library of deglycobleomycins in the Hecht laboratory in 2003 using solid 
phase synthesis.31 As illustrated in Figure 1.5, each of the structural domains of 
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bleomycin participates in key interactions responsible for the efficient binding and 
cleavage of DNA. Four different subunits of bleomycin include a disaccharide subunit, a 
metal binding domain, a linker region, and a C-terminal DNA binding domain, the latter 
of which typically includes a positively charged aliphatic subunit.  
 
Figure 1.5. Schematic of HOO-Co(III)•Bleomycin B2 Highlighting the Metal Binding 
Domain, Linker Region, Disaccharide Moiety and C-Terminal Substituent. Atoms 
involved in H-bonding to the DNA are in red, and atoms involved in intramolecular H-
bonding are in blue.32 
 
 
The disaccharide subunit of bleomycin, composed of L-gulose and D-mannose, 
has been studied for its contribution to cellular recognition and uptake (Figure 1.6).33 
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Recently the Hecht laboratory reported that bleomycin and its carbohydrate moiety, 
conjugated to a cyanine dye, bound selectively to cancer cells.34 It was also shown that 
the carbamoyl functionality in the disaccharide moiety was required for tumor cell 
targeting.34  
 
Figure 1.6. Carbohydrate Moiety of Bleomycin. (a) Structure of BLM A5, in which the 
highlighted domain shows the carbamoylmannose. (b) Structures of BLM 
monosaccharide bound to Cy5** (1), decarbamoyl BLM moiety monosaccharide bound 
to Cy5** (2), and the BLM monosaccharide−Cy5** trimer (3).34 
 
The metal binding domain, consisting of a pyrimidoblamic acid and a β-
hydroxyhistidine moiety, is known to interact with and activate first row transition metal 
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ions, such as Fe, Cu, Co, Mn, Ni, Ru, and V. Recently, in a computational modeling 
based study, Buda et al. described pyrimidoblamic acid as the primary metal chelating 
domain of bleomycin (Figure 1.7).35 These specific domains are also key factors for the 
site-specific binding of bleomycin-DNA interaction (Figure 1.8).16 
 
Figure 1.7. Metal Chelating Domain of Fe(II)•BLM.35 
 
The bleomycin linker region consists of methylvalerate and L-threonine moieties 
and is responsible for preorganization of the molecule for DNA cleavage.36,37 Early 
studies in the Boger38 and Hecht39 laboratories demonstrated that an altered linker region 
in bleomycin confers less sequence selectivity of DNA cleavage and dramatically 
decreases DNA cleavage efficiency.38,39 In a similar study, Hecht and coworkers 
confirmed that the length and nature of the methylvalerate domain of bleomycin also play 
key roles in determining the DNA cleavage efficiency of bleomycin.37 
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Figure 1.8. Interactions of the Metal ̶ Binding Domain and Disaccharide Moiety With 
DNA. (A) Stereodiagram of the minor groove of DNA (gray) shown with the metal ̶ 
binding (yellow with Co in green) and disaccharide (purple) domains and a modeled 
peroxide ligand (cyan) as a ball-and-stick model. Hydrogen bonds are represented as 
dashed lines with interacting O atoms in red and N atoms in blue. Intermolecular bonds 
are black, intramolecular bonds are blue, and magenta bonds represent interactions of the 
propionamide as modeled (the propioanamide is absent in electron density). The red stick 
indicates the connection to the linker domain. (B) Schematic showing the hydrogen 
bonding interactions of the metal ̶ binding and disaccharide domains in the minor groove 
with bonds colored as in A.32 
 
The DNA binding domain of bleomycin has a C-terminal substituent and a 
bithiazole moiety, which interact with DNA and binds to the minor groove, helping the 
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bleomycin molecule to position itself against DNA backbone. In 1985 Henichart et al. 
employed EPR, fluorescence and viscometry techniques with synthetic 2,4-disubstituted 
bithiazoles, structurally related to the "tripeptide S" moiety of bleomycin. They reported a 
partial intercalation of the ring between the base pairs.40 Moreover, a slight decrease of 
DNA length in the presence of bithiazole derivative was also revealed, which led to the 
introduction of a binding model that partially inserts of a thiazole ring in between the 
bases at a binding site of DNA (Figure 1.9).40 
 
Figure 1.9. Proposed Model for the Insertion of the Bithiazole Moiety of Bleomycin into 
the DNA Kink.40 
 
 
In an effort to further understand the interaction between bithiazole and DNA, 
several bithiazole analogues were synthesized in the Hecht laboratory41 for their 
incorporation into deglycobleomycin (Figure 1.10). It was concluded that an intact 
bithiazole moiety is essential for DNA binding and subsequent cleavage.41 A study 
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Figure 1.10. Deglycobleomycin ̶ Containing Monothiazole Analogues.41 
 
in the Hecht laboratory also demonstrated that a trithiazole moiety (Figure 1.11) had 
undergone cleavages at less predominantly observed 5-GT-3 sequences whereas the 
bithiazole moiety was more selective for 5-GC-3 sequences.42  
 
Figure 1.11. Deglycobleomycin With a Trithiazole Moiety.42 
 
 
1.4. Pathway of DNA Cleavage by Bleomycin 
The activation of bleomycin results in a species containing BLM and a metal-oxo 
complex and leads to DNA cleavage by two different pathways (Figure 1.12).43 
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After activation bleomycin initiates DNA cleavage in a sequence-selective manner. The 
process is initiated by the abstraction of the C4 hydrogen atom of a pyrimidine situated 
to the 3-side of a deoxyguanosine. Depending on the availability of oxygen this radical 
can mediate DNA cleavage via two different pathways. The frank strand scission is 
observed in presence of oxygen where oxygen reacts with the formed radical to undergo  
 
Figure 1.12. Pathways of DNA Cleavage by Bleomycin. 
 
a C4-peroxy radical based Criegee-type rearrangement, which results in a DNA lesion 
with a 3-phosphoglycolate, an oligomer with a 5-phosphate and a base propenal. In 
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contrast, the “anaerobic” pathway leads to a transformation producing a 4-
hydroxyapurinic acid moiety and the release of a nucleobase. This abasic site yields an 
oligonucleotide terminating in a 3ʹ-phosphate or 3ʹ-hydroxycyclopentenone moiety, when 
treated with alkali.44-48 
The degradation of DNA by bleomycin is a complex, multistep process and has 
been a subject of ongoing debate over the past few decades. It is postulated that the Fe in 
Febleomycin can cycle repeatedly through Fe(II) and Fe(III) to facilitate a steady 
activation of bleomycin. Research has shown that superoxide and peroxides, as a 
byproduct of frank strand scission, contribute to the process of FeBLM reactivation 
(Figures 1.13 and 1.14).17,49,50  
 
 
Figure 1.13. Possible Activated FeBleomycin Formation Pathways.17 
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Figure 1.14. Proposed Catalytic Cycle of DNA Degradation by BLM.49,50 
 
In my research, a combination of a low concentration of bleomycin, comparable 
to the clinically approved dosage, and a library of hairpin DNAs that strongly bind to 
bleomycin were employed to investigate the biochemistry of bleomycin A5 induced 
double-strand DNA cleavage. 
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CHAPTER 2 
MECHANISM OF BLEOMYCIN INDUCED DOUBLE-STRAND DNA CLEAVAGE 
 
2.1. Introduction 
Even though it is clear from early studies that the cytotoxicity of bleomycin is a 
result of its DNA cleavage activity, and the single-strand mode of cleavage is well 
understood, the nature of DNA double-strand breakage has not been as well 
characterized. In DNA cleavage by bleomycin, a secondary coupled cleavage has been 
observed at the site on the opposite strand directly opposing the primary lesion, occurring 
at the frequency of 20% of the total DNA cleavage. 
For primary cleavage sites containing a 5-G-Py-Pu-3 sequence, a break at the Py 
usually results in a secondary break at the base directly opposite to the Pu, leaving a 
single-base 5-extension. For primary cleavage sites containing a 5-G-Py-Py-3 sequence, 
a break at the Py usually results in a secondary break at the base directly opposite to the 
Py, creating a blunt end. As proposed by Povirk et al.,49 this model posits that after the 
primary cleavage event by bleomycin, the resulting Fe(III)•BLM product and peroxyl 
radical regenerates activated Fe•BLM in order to perform a secondary cleavage on the 
opposite DNA strand through a reorganization of DNA binding without dissociation of 
the BLM from the DNA (Figure 2.1).51  
                     
Figure 2.1. Double-Strand DNA Cleavage Patterns Exhibited by BLM.51 
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In the Hecht laboratory, a model of BLM mediated double-stranded DNA 
cleavage was developed, based on the structural determination of Zn(II)•BLM A2 bound 
to the self-complementary Dickerson-Drew dodecamer, by 2D NMR and molecular 
modeling (Figure 2.2). The findings were further reinforced by biochemical studies 
involving Fe(II)•BLM A2.52 According to this model, BLM mediates double-strand 
cleavage of this DNA without structural reorganization. Fe(II)•BLM A2 mediated 
cleavage of the Dickerson ̶ Drew dodecamer results in the appearance of two major 
cleavage sites, 5ʹ-GA5-3ʹ on one DNA strand and 5ʹ-GC11-3ʹ on the other DNA strand. In 
the 1H NMR spectrum, intermolecular NOE contacts between the Dickerson-Drew 
dodecamer and the metal binding domain of Zn(II)•BLM A2 placed the C4ʹ hydrogens of 
A5 and C11 oriented towards each other in the minor groove as well as at relatively equal 
distances from the metal center of the Zn(II)•BLM A2 (Figure 2.2).52 While structural 
variations between Zn(II)•BLM and Fe(II)•BLM must be taken into account, the 
correlation of NMR data and cleavage site analysis strongly support a model of BLM 
mediated double-strand DNA cleavage occurring without reorganization of the BLM on 
the DNA oligonucleotide. 
 
 
Figure 2.2. NMR Model of DNA-Bleomycin Interaction Revealing the Potential Site of a 
Double-Strand Break.52 
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Based on the previous findings in Hecht laboratory, the study of dsDNA cleavage 
was extended to a library of hairpin DNAs (Table 2.1)53, selected for having high binding 
affinity to bleomycin A5. All of the hairpin  DNAs undergo multiple double-strand DNA 
cleavage events.  Interestingly some of these cleavages involve a novel mechanism, not 
described before.  
Table 2.1. Sequence of 10 Hairpin DNAs.53 
 
 
2.2.  Results 
In a previous report we showed the bleomycin A5 cleavage sites on the 10 hairpin 
DNAs (Figure 2.3).54 To extend our knowledge further to bleomycin-induced double-
strand cleavages, the hairpin DNA library seemed to be the ideal model. Each of these 
DNAs were alternatively labeled at 5ʹ-and 3ʹ-ends using 32P-phosphate and subjected to  
5 µM Fe(II)•bleomycin treatement for 30 minutes, following the method described in 
section 2.4. The double-strand cleavage products appeared as co-migrating bands when 
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analyzed on a native gel. When subsequently analyzed on a denaturing gel, the sites of 
cleavage could be determined at single nucleotide resolution.  
 
 
Figure 2.3. Sites of BLM-Mediated Damage for the Ten Hairpin DNAs Studied.54 
 
The chemistry of coupled double-strand cleavage has been studied over a number 
of years16,17,55 and is illustrated in Scheme 2.1. The scheme illustrates an outline of the 
products formed at every step of bleomycin-induced DNA cleavage resulting in double-
strand lessions. As evident in Scheme 2.1, the initial BLM induced lesion can produce an 
alkali labile lesion (product I), or to progress the strand scission process leading to a 
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nicked DNA duplex (product II). The nicked DNA can undergo a second Fe(II)•BLM 
mediated oxidative cleavage on the opposing strand of the DNA duplex, in close 
proximity to the first lesion (product IV), or to an alkali labile lesion (product III), 
depending on the availability of oxygen. Although product IV results in double-strand 
cleavage, treatment of III with n-butylamine would also lead to double-strand cleavage 
(product V).  
 
Scheme 2.1. Mechanisms of Fe•Bleomycin Induced Double-Strand DNA Cleavage.56 
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DNA 8, having multiple putative dsDNA cleavage sites, was chosen for the initial 
experiment. As shown in Figure 2.4, treatment with Fe•bleomycin A5 formed three 
double-strand DNA cleavage products (b, c and d in lanes 2 and 4). It was also observed 
that the amounts of all of those cleavage products were enhanced following additional 
treatment with n-butylamine (products b, c and d in lanes 3 and 5), while the bands 
representing the full-length hairpin DNAs (a in lanes 2 and 4) were reduced in intensity. 
As illustrated in Figure 2.4 the species which co-migrate with full-length hairpin DNA (a 
in lanes 2, 3, 4 and 5) are products of type I, II and III (Scheme 2.1), with residual 
amounts of the unreacted full-length hairpin DNA. 
 
Figure 2.4. Double-Strand Cleavage of [5-32P]-End Labeled (lanes 1 – 3) and [3-32P]-
End Labeled (lanes 4 – 6) 64-Nucleotide Hairpin DNA 8 by Fe(II)•BLM A5. Lane 1, [5-
32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)•BLM A5; lane 3, 5 µM Fe(II)•BLM A5 
+ 2 mM n-butylamine; lane 4, 5 µM Fe(II)•BLM A5; lane 5, 5 µM Fe(II)•BLM A5 + 2 
mM n-butylamine; lane 6, [3-32P]-end labeled DNA alone.56 
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The positions of dsDNA cleavage in Figure 2.4 (bands b, c and d) were assigned 
by isolating each of the bands from the native gel and analyzing them in a 20% 
denaturing polyacrylamide gel in direct comparison with a Maxam ̶ Gilbert G+A 
sequencing lane (Figure 2.5).  As shown in Figure 2.5, the [3-32P]-end labeled band 4b 
(Figure 2.4) co-migrated with the band in the sequencing lane corresponding to cleavage 
at T50 (Figure 2.5). Similarly, the product treated with n-butylamine (5b) was also cleaved 
at T50. Likewise, the other two bands (4c and 4d) were found to be cleaved at positions 
C52 and T56. As shown in lane 2 of Figure 2.5, product 4a produced bands which co-
migrated with the products derived from 4b, 4c and 4d, indicating that the duplex in 4a 
only contained products with strand scission at those positions (T50, C52 and T56) without 
any complementary cleavages on the opposite strand, suggesting that three sites represent 
primary sites of cleavage. 
Following a similar process, [5′-32P]-end labeled products derived from hairpin 
DNA 8 were identified. As shown in Figure 2.5 (lanes 9, 11 and 12), the products in 
bands 2b, 2c and 2d (Figure 2.4) were cleaved at T14, G12 and A9, respectively. This 
suggests that the double-strand cleavage product represented in band b (Figure 2.4) must 
have resulted from cleavage at T14 and T50. Similarly, the product in band c resulted from 
cleavage at G12 and C52, whereas cleavage at A9 and T56 resulted in band d. The 
sequences of the double-strand cleavage products in DNA 8 and all the other members of 
the library are summarized in Figure 2.6. Additionally, as shown in lane 8 of Figure 2.5, 
band 2a (from Figure 2.4) co-migrated with bands corresponding to A9, G12 and T14 
(Figure 2.5), suggesting that each of these positions can also be primary sites of cleavage. 
 22 
Thus analysis of the dsDNA cleavage of DNA 8 indicates the absence of any obligatory 
order of cleavage seen in previous studies. 
 
 
Figure 2.5 Sequencing Gel Analysis of Fe(II)•BLM A5-Induced Double-Strand Cleavage 
Sites of [3-32P]-End Labeled (lanes 1-6) and [5-32P]-End Labeled (lanes 7-12) DNA 8. 
Each lane (except lanes 1 and 7) corresponds to a numbered cleavage band, shown in Fig. 
2.4 Lane 1, Maxam ̶ Gilbert G+A sequencing lane of [3-32P]-end labeled DNA 8; lane 2, 
band 4a; lane 3, band 4b; lane 4, band 5b; lane 5, band 4c; lane 6, band 4d; lane 7, 
Maxam ̶ Gilbert G+A sequencing lane of [5-32P]-end labeled DNA 8; lane 8, band 2a; 
lane 9, band 2b; lane 10, band 3b; lane 11, band 2c; lane 12, band 2d.56 
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Figure 2.6. Summary of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNAs 1-10. Orange bases indicate the randomized region of the original hairpin 
DNA library. Arrows of the same shape and color indicate paired cleavages. Black 
arrows correspond to coupled double- strand cleavage events whereas red arrows indicate 
non-coupled double-strand cleavage events, which results from two independent single-
strand cleavages on opposite strands. Nucleotides colored in red indicate primary sites of 
double-strand cleavage.56 
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As shown in Figure 2.7, five new bands appeared when hairpin DNA 2 was 
treated with Fe(II)•BLM A5. Each of the five bands in lanes 2 and 3 along with the bands 
(2a and 3a) co-migrating with unreacted DNA were isolated and subjected to analysis by 
denaturing polyacrylamide gel electrophoresis. 
 
 
 
Figure 2.7. Double-Strand Cleavage of [3-32P]-End Labeled (lane 2) and [5-32P]-End 
Labeled (lane 3) 64-Nucleotide Hairpin DNA 2 by Fe•BLM A5. Lane 1, [3-32P]-end 
labeled DNA alone; lane 2, 5 µM Fe(II)•BLM A5; lane 3, 5 µM Fe(II)•BLM A5; lane 4, 
[5-32P]-end labeled DNA alone.56 
 
As shown in Figure 2.8, the [5′-32P]-end labeled DNA 2, when treated with 
bleomycin, was cleaved at positions A9, T13, A15, C16 and C18, whereas the [3′-32P]-end 
labeled bleomycin treated DNA 2 was cleaved at positions T46, C48, T50, C51 and T56. Co-
migrating bands suggests that DNA 2 involved dsDNA cleavage at T46/C18, C48/C16, 
T50/A15, C51/T13 and T56/ A9. The sequences of dsDNA cleavage products are summarized 
in Figure 2.6. 
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Figure 2.8. Sequencing Gel Analysis of Fe•Bleomycin Induced Double-Strand Cleavage 
Sites of [3-32P]-End Labeled (lanes 1-7) and [5-32P]-End Labeled (lanes 8-14) Hairpin 
DNA 2. Each lane (except lanes 1 and 8) corresponds to a numbered cleavage band, 
shown in Figure 2.7. Lane 1, Maxam ̶ Gilbert G+A sequencing lane of [3-32P]-end 
labeled DNA 2; lane 2, band 2f; lane 3, band 2e; lane 4, band 2d; lane 5, band 2c; lane 6, 
band 2b; lane 7, band 2a; Lane 8, Maxam ̶ Gilbert G+A sequencing lane of [5-32P]-end 
labeled DNA 2; lane 9, band 3f; lane 10, band 3e; lane 11, band 3d; lane 12, band 3c; 
lane 13, band 3b; lane 14, band 3a.56 
 
Additionally, analysis of 3a (Figure 2.7) by denaturing polyacrylamide gel 
electrophoresis (Figure 2.8) indicated cleavage at positions C48 and T50. In comparison, 
analysis of band 4a (Figure 2.7) indicated cleavage at positions T13 and C18 (Figure 2.8). 
As noted in Scheme 2.1, these bands must represent sites nicked to produce intermediates 
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of type II or III (Scheme 2.1), without associated cleavage on the opposite strand, thus 
indicating primary sites of cleavages.  Similarly, bands 2f/3f, when compared in a 
denaturing gel (Figure 2.8), showed little partially cleaved material corresponding to 
products derived from bands 2a/3a suggesting that the cleavages at A9 and T56 represent 
independent single strand cleavage events, resulting in adventitious dsDNA cleavage 
product. In comparison, the rest of the cleavage sites (T13/C51, A15/T50, C16/C48 and 
C18/C46) appeared to be coupled dsDNA cleavages with obligatory primary sites, 
consistent with the mechanism described previously.57 
The remaining eight hairpin DNAs in a library were also analyzed in a similar 
fashion to establish patterns of double-strand cleavage by Fe(II)•BLM A5. Among the 
original 14 cleavage sites in hairpin DNA 1 (Figure 2.3),54 six sites were located within 
the original eight base-pair randomized region that had been used to create the random 
DNA library.57 Interestingly, native gel analysis revealed only one double-strand cleavage 
product (Figure 2.9A). Further analysis of the cleavage products (Figure 2.9B) revealed 
that bands 2b and 3b in Figure 2.9A, contained a mixture of two sets of products, 
resulting from cleavages at A9/T56 and T10/A55 neither of which resulted from coupled 
double-strand cleavage. 
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Figure 2.9. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on Hairpin 
DNA 1. (A) Double-strand cleavage of [3-32P]-end labeled (lanes 1 and 2) and [5-32P]-
end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 1 by bleomycin A5. Lane 1, [3′-
32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM Fe(II)BLM A5; 
lane 4, [5-32P]-end labeled DNA alone. (B) Sequencing gel analysis of bleomycin 
induced double-strand cleavage sites on [3-32P]-end labeled (lanes 1-3) and [5-32P]-end 
labeled (lanes 4-6) DNA 1. Each lane (except lanes 3 and 4) corresponds to a numbered 
cleavage band, shown in (A). Lane 1, band 2b; lane 2, band 2a; lane 3, Maxam ̶ Gilbert 
G+A sequencing lane of [3-32P]-end labeled DNA 1; lane 4, Maxam ̶ Gilbert G+A 
sequencing lane of [5-32P]-end labeled DNA 1; lane 5, band 3b; lane 6, band 3a.56 
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Hairpin DNA 3, shown in Figure 2.6, displayed two pairs of co-migrating bands 
in the native polyacrylamide gel analysis (Figure 2.10A). Further analysis of those bands 
by denaturing polyacrylamide gel electrophoresis (Figure 2.10B) indicated that they are 
the products from coupled double-strand cleavage at T15/C49, having T15 as the primary 
site of cleavage and non-coupled double-strand cleavage involving T10 and A55. 
 
 
Figure 2.10. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 3. (A) Double strand cleavage of [3-32P]-end labeled (lanes 1 and 2) and 
[5-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 3 by bleomycin A5. Lane 
1, [3-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3-32P]-end labeled (lanes 1-4) and 
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[5-32P]-end labeled (lanes 5-8) DNA 3. Each lane (except lanes 1 and 5) corresponds to a 
numbered cleavage band, shown in (A). Lane 1, Maxam ̶ Gilbert G+A sequencing lane of 
[3-32P]-end labeled DNA 3; lane 2, band 2a; lane 3, band 2b; lane 4, band 2c; Lane 5, 
Maxam ̶ Gilbert G+A sequencing lane of [5-32P]-end labeled DNA 3; lane 6, band 3a; 
lane 7, band 3b; lane 8, band 3c.56 
 
     Similarly, hairpin DNA 4 showed two double-strand cleavage bands (Figure 2.11A). 
Each of the bands when, analyzed on a denaturing polyacrylamide gel (Figure 2.11B), 
revealed dsDNA cleavage at A9/T56 and T10/A55. Analysis of bands 2a and 3a containing 
unreacted products suggested that neither was involved in a coupled double-strand 
cleavage event.  
 
 
Figure 2.11. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 4. (A) Double strand cleavage of [3-32P]-end labeled (lanes 1 and 2) and 
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[5-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 4 by bleomycin A5. Lane 
1, [3-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3-32P]-end labeled (lanes 1-4) and 
[5-32P]-end labeled (lanes 5-8) DNA 4. Each lane (except lanes 4 and 8) corresponds to a 
numbered cleavage band, shown in (A). Lane 1, band 2c; lane 2, band 2b; lane 3, band 
2a; lane 4, Maxam ̶ Gilbert G+A sequencing lane of [3-32P]-end labeled DNA 4; lane 5, 
band 3c; lane 6, band 3b; lane 7, band 3a; lane 8, Maxam ̶ Gilbert G+A sequencing lane 
of [5-32P]-end labeled DNA 4.56 
 
Hairpin DNA 5 exhibited three sets of double-strand cleavages (Figure 2.12A), 
although a total of 27 sites of bleomycin A5 mediated cleavages had been reported earlier 
(Figure 2.3).54 Each of these bands, on a denaturing polyacrylamide gel (Figure 2.12B), 
indicated a single duplex resulting from double-strand cleavage at C12/T54, T10/T56 and 
A15/T49. Only the site involving C12/T54 represented a coupled double strand cleavage 
event, with T54 being the primary cleavage site.  
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Figure 2.12. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 5.  (A) Double strand cleavage of [3′-32P]-end labeled (lanes 1 and 2) and 
[5′-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 5 by bleomycin A5. Lane 
1, [3′-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5′-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3′-32P]-end labeled (lanes 1-5) and 
[5′-32P]-end labeled (lanes 6-10) DNA 5. Each lane (except lanes 5 and 10) corresponds 
to a numbered cleavage band, shown in (A). Lane 1, band 2d; lane 2, band 2c; lane 3, 
band 2b; lane 4, band 2a; lane 5, Maxam ̶ Gilbert G+A sequencing lane of [3′-32P]-end 
labeled DNA 5; lane 6, band 3d; lane 7, band 3c; lane 8, band 3b; lane 9, band 3a; Lane 
10, Maxam ̶ Gilbert G+A sequencing lane of [5′-32P]-end labeled DNA 5.56 
 
The study of hairpin DNA 6, as illustrated in Figure 2.13A, revealed two putative 
double-strand cleavage products. Analysis of those bands revealed two sets of dsDNA 
cleavage products one of which involves T12 and T52, with T52 being the primary site of 
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cleavage. The second dsDNA cleavage product at A9 and T56, resulted from non-coupleed 
dsDNA cleavage with no obligatory primary site of cleavage. 
 
Figure 2.13. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 6. (A) Double strand cleavage of [3′-32P]-end labeled (lanes 1 and 2) and 
[5′-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 6 by bleomycin A5. Lane 
1, [3′-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5′-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3′-32P]-end labeled (lanes 1-4) and 
[5′-32P]-end labeled (lanes 5-8) DNA 6. Each lane (except lanes 1 and 5) corresponds to a 
numbered cleavage band, shown in (A). Lane 1, Maxam ̶ Gilbert G+A sequencing lane of 
[3′-32P]-end labeled DNA 6; lane 2, band 2a; lane 3, band 2b; lane 4, band 2c; lane 5, 
Maxam ̶ Gilbert G+A sequencing lane of [5′-32P]-end labeled DNA 6; lane 6, band 3a; 
lane 7, band 3b; lane 8, band 3c.56 
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The five double-strand cleavage products from DNA 7 (Figure 2.14) observed on 
a native polyacrylamide gel (Figure 2.14A), were isolated and analyzed on a denaturing 
polyacrylamide gel (Figure 2.14B). Three duplex products resulted from 
 
 
 
Figure 2.14. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 7. (A) Double-strand cleavage of [3′-32P]-end labeled (lanes 1 and 2) and 
[5′-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 7 by bleomycin A5. Lane 
1, [3′-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5′-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3′-32P]-end labeled (lanes 1-7) and 
[5′-32P]-end labeled (lanes 8-14) DNA 7. Each lane (except lanes 1 and 14) corresponds 
to a numbered cleavage band, shown in (A). Lane 1, Maxam ̶ Gilbert G+A sequencing 
lane of [3′-32P]-end labeled DNA 7; lane 2, band 2a; lane 3, band 2b; lane 4, band 2c; 
lane 5, band 2d; lane 6, band 2e; lane 7, band 2f; Lane 8, band 3f; lane 9, band 3e; lane 
10, band 3d; lane 11, band 3c; lane 12, band 3b; lane 13, band 3a; lane 14, Maxam ̶ 
Gilbert G+A sequencing lane of [5′-32P]-end labeled DNA 7.56 
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coupled double-strand cleavage events. These included sites involving T11/T53, C13/C51 
and C17/T47. In these, T53, C51 and C17 were the primary sites of cleavages. The other 
double-strand cleavage products involving cleavage at T10/A55 and C15/C49 represented 
non-coupled dsDNA cleavage events. 
  When DNA 9 (Figure 2.15) was analyzed for dsDNA cleavage as shown in Figure 
2.15A, three double-strand cleavage products were observed. The denaturing 
polyacrylamide gel (Figure 2.15B) of those bands indicated that the sites involved 
cleavage at T10/A55, T13/A52 and T16/A49. Analysis of the mixed products 2a and 3a 
(Figure 2.15A) revealed four primary sites of cleavages at T10, T13, T16 and A55 (Figure 
2.15B), suggesting that cleavage at T13/A52 and T16/A49 represent coupled dsDNA 
cleavage events whereas that at T10/A55 indicates a non-coupled event. 
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Figure 2.15. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 9. (A) Double-strand cleavage of [3′-32P]-end labeled (lane 2) and [5′-32P]-
end labeled (lane 3) 64-nucleotide hairpin DNA 9 by Fe•bleomycin A5. Lane 1, [3′-32P]-
end labeled DNA alone; lane 2, 5 µM Fe(II)•BLM A5; lane 3, 5 µM Fe(II)•BLM A5; lane 
4, [5′-32P]-end labeled DNA alone. (B) Sequencing gel analysis of Fe•bleomycin-induced 
double-strand cleavage sites of [3′-32P]-end labeled (lanes 1-5) and [5′-32P]-end labeled 
(lanes 6-10) hairpin DNA 9. Each lane (except lanes 5 and 10) corresponds to a 
numbered cleavage band, shown in (A). Lane 1, band 2d; lane 2, band 2c; lane 3, band 
2b; lane 4, band 2a; lane 5, Maxam ̶ Gilbert G+A sequencing lane of [3′-32P]-end labeled 
DNA 9; lane 6, band 3d; lane 7, band 3c; lane 8, band 3b; lane 9, band 3a; Lane 10, 
Maxam ̶ Gilbert G+A sequencing lane of [5′-32P]-end labeled DNA 9.56 
 
The last member of the library, DNA 10, showed three double-strand cleavage 
products after Fe•BLM treatment as shown in Figure 2.16A. The co-migrating bands, 
when analyzed on a denaturing polyacrylamide gel (Figure 2.16B), indicated two 
separate coupled, double-strand cleavages. The cleavage sites involved C11/C53, with the 
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latter being the primary site of cleavage and at C13/G52, with the former being the primary 
site. The third product, involving T10/A55 was a non-coupled cleavage event with no 
preferred primary cleavage site.  
 
 
Figure 2.16. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 10. (A) Double-strand cleavage of [3′-32P]-end labeled (lanes 1 and 2) and 
[5′-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 10 by bleomycin A5. 
Lane 1, [3′-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [5′-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [3′-32P]-end labeled (lanes 1-5) and 
[5′-32P]-end labeled (lanes 6-10) DNA 10. Each lane (except lanes 1 and 6) corresponds 
to a numbered cleavage band, shown in (A). Lane 1, Maxam ̶ Gilbert G+A sequencing 
lane of [3′-32P]-end labeled DNA 10; lane 2, band 2a; lane 3, band 2b; lane 4, band 2c; 
lane 5, band 2d; lane 6, Maxam ̶ Gilbert G+A sequencing lane of [5′-32P]-end labeled 
DNA 10; lane 7, band 3a; lane 8, band 3b; lane 9, band 3c; Lane 10, band 3d.56 
 
 37 
2.3.  Discussion 
 Although bleomycin has been used as an antitumor agent for decades, the 
mechanism by which it exerts its therapeutic effect has never been fully established. 
Additionally, the very small clinical dose also suggests the presence of multiple highly 
specific mechanisms to achieve tumor cell killing. The recent use of a hairpin DNA 
library, selected for tight binding to the drug, in bleomycin cleavage studies has 
confirmed our early findings that model hairpin DNAs having a single strong bleomycin 
binding site can be cleaved in multiple places.58 Additionally, we found that those 
cleavages include numerous double-strand cleavages, which may suggest a mechanism 
for tumor cell killing. 
Bleomycin induced double-strand cleavage of DNA was first studied extensively 
by the Povirk laboratory.51,59-61 In their study, three linear DNA duplexes containing 250 
base pairs were analyzed for dsDNA cleavages, which showed 26 double-strand DNA 
cleavage sites. The sites of double-strand cleavage, resulting from treatment with 
Fe(II)•BLM A2, were analyzed by separation of the DNA fragments on a native 
polyacrylamide gel. An analysis of each of the bands following 5 or 3-32P-end labeling 
was carried out using a sequencing gel. With one exception, all of the double-strand 
breaks showed a G-Py sequence on one strand and a much greater diversity of cleavage 
products on the other strand. Interestingly, eleven of the dsDNA cleavages produced 
blunt-end products, whereas twelve of them resulted in products with one nucleotide 5′-
extensions.51 
 As they had maintained the condition of single hit kinetics throughout their 
studies, Povirk et al.51 concluded that each dsDNA cleavage observed in their analysis 
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must have resulted from the action of a single bleomycin molecule. The appearance of a 
G-Py sequence virtually in all of the dsDNA cleavages suggested that this must be the 
primary site of cleavage. The occasional formation of alkali labile lesions was also 
observed by the researchers at the secondary sites. In a different study by Keller and 
Oppenheimer, an enhanced cleavage opposite to an initial bleomycin-induced nick had 
also been reported. 62 Absalon et al.63,64 explained the nature of dsDNA cleavages in a 
more detailed way in a subsequent study, utilizing hairpin DNA oligonucleotides. 
Employing the technique of labeling their hairpin DNAs internally at a 32P-labeled 
phosphate, they were able to determine the ratio of single-strand and double-strand 
cleavage at each individual site. Replacing the C-4 H atom, susceptible to abstraction by 
Fe•BLM by deuterium in putative bleomycin cleavage site, they concluded that 
bleomycin induced dsDNA cleavage results from a single bleomycin molecule and 
requires reactivation of bleomycin after the first cleavage event (Figure 2.17). 
 In a previous study we reported a hairpin DNA with one bleomycin cleavage site 
that undergoes highly efficient cleavage at that site.52 The method involved alternatively 
labeling the hairpin DNAs at 5- and 3-ends with a radiolabeled 32P-ATP. For coupled 
dsDNA cleavage events (Figure 2.17) the ratio of cleavage products observed for the two 
labeled hairpin DNAs varied dramatically, which enabled quantification of frank-strand 
scission and alkali labile lesion.  
 In our present study, the alternatively labeled 5 and 3-end cleavage products also 
produced bands of different intensities on the native gel, suggesting that some of those 
cleavages involve dsDNA cleavages. However, presence of a large number of dsDNA 
cleavage bands in the hairpin DNAs prompted us to employ a modified technique similar 
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to one described by Povirk et al.51 In addition to studying the bands containing dsDNA 
cleavage products, we also analyzed the bands at the top of each cleavage lanes on a non-
denaturing polyacrylamide gel. As described in Scheme 2.1, these bands contained a 
mixture of products with unreacted hairpin DNA. Among all the different types of 
products in the mixture, product III (Scheme 2.1) had a frank strand scission on a primary 
site of bleomycin cleavage and an alkali labile lesion on the other strand, affording a 
hairpin DNA nicked at the primary site. As suggested by Povirk et al.,51  product III 
resulted from reactivation of a bleomycin molecule after the frank strand scission at the 
primary site, leading to an alkali labile lesion on the second strand instead of a second 
strand break. Product III also carries the information of a primary bleomycin induced 
dsDNA cleavage site when analyzed on a denaturing polyacrylamide gel. As illustrated in 
Figure 2.3, treatments of bands 2a and 3a with n-butylamine resulted in additional 
dsDNA cleavage products in lanes 3 and 5, which suggested the presence of product III. 
 Additionally, coupled double-strand bleomycin cleavage events were identified 
by analyzing the top bands from each native gel. As shown in Figure 2.15, the DNA 
cleavage product III gave a band at the primary cleavage site on a denaturing 
polyacrylamide gel, which came from the singly nicked DNA. The strand containing the 
alkali labile lesion failed to produce a similar band on a denaturing gel, confirming that it 
was a secondary site of cleavage. These phenomena were further illustrated in Figure 
2.15B. 3-32P-end labeled DNAs recovered from bands 2d, 2c and 2b (Figure 2.15A), 
respectively, revealed the sites of bleomycin induced dsDNA cleavage at the 3 labeled 
side of the hairpin DNAs at A55, A52 and A49, respectively (lanes 1, 2 and 3 in Figure 
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2.15B). Lane 4 of Figure 2.15 B, containing band 2a from Figure 2.15A, showed a strong 
cleavage at A55, but weak cleavages at A52 and A49. Similarly, lanes 6, 7 and 8 of  
        
Figure 2.17. Bleomycin Induced Double-Strand DNA Lesion Progresses Through Either 
(A) A Coupled Cleavage Event or (B) A Non-Coupled Cleavage Event. The coupled 
DNA cleavage is mediated by a single BLM molecule, which is reactivated after the 
primary lesion to produce a secondary cleavage on the opposing strand of DNA, without 
dissociating from the site of cleavage. The non-coupled cleavage is mediated by two 
BLM molecules, and involves independent activation and association of BLM molecules 
with cleavage sites, closely situated on the opposing strands of DNA. 
 
Figure 2.15B contained 5-32P-end labeled cleavage products recovered from bands 3d, 3c 
and 3b, respectively (Figure 2.15A). Those bands readily revealed the sites of bleomycin 
induced dsDNA cleavage on the 5 side of the hairpin DNA at T10, T13 and T16, 
respectively. Lane 9 (Figure 2.15B), containing product 3a (Figure 2.15A), produced 
strong bands at sites T10, T13 and T16. The absence of intense bands at A52 and A49 at the  
BLM-treated 3-32P-end labeled side of the hairpin DNA suggests that these sites 
contained alkali labile lesions (lane 4, Figure 2.15A). Additionally it proves that 
cleavages at T13/A52 and T16/A49 are coupled with T13 and T16 as the primary sites of 
cleavage. The appearance of both the cleavage partners of the A55/ T10 in lanes 4 and 9, 
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respectively suggests that either of these sites can act as a primary site of cleavage in a 
dsDNA cleavage event or they result from two independent single strand cleavages 
induced by two separate bleomycin molecules, resulting in an adventitious dsDNA 
cleavage. Although the reactions were not carried out under single-hit kinetic condition to 
assure whether the cleavages at T10/A55 involved a single bleomycin molecule, the earlier 
observations made by Povirk suggest that the cleavage at T10/A55 represented two 
independent events. 
 In the study of dsDNA cleavage done by Povirk et al.,51 all but one of the dsDNA 
cleavage sites involved a G-Py sequence as one of the cleavage sites and the opposing 
strand mostly involved a non-conventional site, not usually seen as a single-strand 
cleavage site. In our present study all 14 confirmed coupled double-strand cleavage 
events involved a G-Py sequence as a primary site. In the previous study, seven of the 
cleavages had a G-Py-Py-Pu sequence as the primary site with the initial cleavage at the 
first Py residue following the guanosine. The subsequent cleavage on the opposing strand 
produced blunt ended products. Six of the other cleavages involved G-Py-Py-Pu 
sequences and the cleavage at the first Py resulted in either blunt-end products or 
products with a single-base 5 overhang on the opposing strand. In our study, four of the 
cleavage products involved G-Py-Py-Pu sequences and none had G-Py-Py-Py sequences 
(Table 2.2). In the earlier study, six of the dsDNA cleavages were also found at G-Py-Pu-
Py sequences, whereas three at G-Py-Pu-Pu sequences. In all of those cleavages, the 
strand scission resulted in products with one-base 5 overhangs. In the current study, three 
of the double-strand events involved G-Py-Pu-Py sequences and, more interestingly, 
seven of the 14 cleavages involved G-Py-Pu-Pu sequences (Table 2.2). Overall, our 
 42 
recent study produced similar results as those reported by Povirk et al.,51 although the 
frequency of double-strand cleavages on DNAs strongly bound by bleomycin was 
somewhat greater than reported earlier.  
 
Table 2.2. Coupled Double-Strand BLM Cleavage Sites in Hairpin DNAs 1 – 10a 
 
aCleavage sequences aligned with primary G-Py cleavage sites.56 
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 Besides the coupled double-strand cleavages summarized in Table 2.1, the other 
17 non-coupled dsDNA cleavages (Figure 2.17B) illustrated in Table 2.3 are  
 
Table 2.3. Non-Coupled Double-Strand BLM Cleavage Sites in Hairpin DNAs 1 – 10a 
 
aAll sequences aligned from 5′-end of hairpin DNAs.56 
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unprecedented. None of these cleavages was of a type previously observed by Povirk et 
al.51 in their early studies. Interestingly, no sequence preferences have been observed in 
this particular kind of cleavage other than an appearance at AT-rich sequences. Most of 
these cleavages occurred at the non-randomized region of the hairpin DNAs, and were 
concluded to be a result of experimental design. However, a few of those cleavages 
occurred in the randomized regions of the hairpin DNAs, such as GAGA in DNA 4, a 
GAAT in DNA 5 and a GCGC in DNA 7.  The only exception was DNA 8, which had 
two of those sites in the eight base pair long variable region, identified as GTAC and 
GGGT. 
 In a recent report, we have used three of those DNAs in a study involving surface 
plasmon resonance to elucidate bleomycin binding sites on those DNAs.58 DNAs 2, 4 and 
5 in that study revealed one strong bleomycin binding site on each of those DNAs and a 
few weak binding sites. In our current study, each of those DNAs was observed to 
undergo multiple cleavages in close proximity, including single and double strand 
cleavage. The competition experiment involving DNA 2 and a 16-nucleotide hairpin 
DNA with a single bleomycin cleavage site indicated that even though bleomycin 
dissociates from the cleavage site on DNA 2, detectable by surface plasmon resonance 
spectroscopy (SPR), it did not cleave the 16-nucleotide hairpin DNA when both were 
present at the same concentration. 
 The model derived from these observations suggests that the hairpin DNAs are 
closely associated with Fe•BLM, even when not bound to them as judged by SPR. This 
strong association of bleomycin with the hairpin DNAs apparently provides enough 
opportunity for multiple cleavages in close proximity to the site of interaction. In our 
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study, both DNA 2 and 7, being the tightest binders57 of bleomycin A5 underwent five 
pairs of dsDNA cleavages whereas the DNAs 1, 3 and 6, being weak binders,57 produced 
two dsDNA cleavages. Chromosomal DNAs may have regions, which bind to Fe•BLM 
more tightly than any DNA used in our study. Assuming that the pattern of bleomycin-
induced dsDNA cleavage seen in the present study is more general, those regions in the 
chromosome may undergo extensive dsDNA cleavage, leading to deletions in gene 
structure. These deletions being difficult to repair may potentially be the cause of cell 
death, which would explain the potency of Fe•bleomycin in tumor cell killing. 
 
2.4.  Experimental 
2.4.1. Materials.  
T4 polynucleotide kinase was purchased from New England Biolabs. 
Recombinant terminal deoxynucleotidyl transferase was obtained from Roche. [γ-32P]-
ATP and [α-32P]-cordycepin were purchased from Perkin Elmer. Fe(NH4)2(SO4)2•6H2O  
and Chelex 100 were from Sigma Aldrich. The hairpin DNAs were obtained from 
Integrated DNA Technologies, Inc. 
 
2.4.2. End Labeling and Purification of Hairpin DNAs.  
The hairpin DNAs were end labeled using [γ-32P]ATP + T4 polynucleotide kinase 
and [α-32P]-cordycepin + terminal deoxytransferase at the 5ʹ and 3ʹ -ends, respectively. 
Ten pmol of 64-nucleotide hairpin DNAs were [5ʹ-32P]-end labeled by incubation with 20 
units of T4 polynucleotide kinase and 0.06 mCi [γ-32P]ATP (specific activity 6000 Ci 
(222 TBq)/mmol) in 50 μL (total volume) of 70 mM Tris-HCl buffer, pH 7.6, containing 
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10 mM MgCl2 and 5 mM DTT. The reaction mixture was incubated at 37 °C for 1 h 
followed by DNA purification by 16% polyacrylamide gel electrophoresis at 1800 V for 
2.5 h. The [3ʹ-32P]-end labeling was done by incubating 10 pmol of hairpin DNA with 20 
units of terminal deoxynucleotidyl transferase and 0.06 mCi [α-32P]-cordycepin (specific 
activity 6000 Ci (222 TBq)/mmol) in 50 μL (total volume) of 70 mM Tris-HCl buffer, pH 
7.6, containing 10 mM MgCl2, 10 mM CoCl2 and 5 mM DTT. The reaction mixture was 
incubated at 37 °C for 1 h followed by purification of DNA by 16% polyacrylamide gel 
electrophoresis at 1800 V for 2.5 h. 
 
2.4.3. Double-Strand DNA Cleavage of Hairpin DNAs.  
Bleomycin cleavage of [5ʹ-32P]- and [3′-32P]-end labeled hairpin DNAs was 
performed by incubating the hairpin DNAs (~30000 cpm) with 5 μM Fe2+ and 5 μM 
bleomycin A5 at 25 
oC for 30 min in a solution containing 10 μL of 2 mM MgCl2 and 10 
mM Na cacodylate, pH 7.0. Two μL of native gel loading buffer containing 0.25% 
bromophenol blue, 0.25% xylene cyanol and 40% D-sucrose were added to the reaction 
mixture, which was separated on a 20% native polyacrylamide gel (200 V, 16 h, 4 °C ). 
Double-strand cleavage sites were identified by visualizing gels using a phosphorimager. 
 
2.4.4. n-Butylamine Treatment of Hairpin DNA 8.  
Bleomycin cleavage reactions of [5′-32P]-end and [3′-32P]-end labeled DNA 8 
were further treated with 2 mM n-butylamine and incubated at 25 oC for 10 min. The 
supernatants were removed under diminished pressure and, DNA pellets were washed 
with 10 μL of deionized water. The final solutions were mixed with 2 μL of native gel 
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loading buffer containing 0.25% bromophenol blue, 0.25% xylene cyanol and 40% D-
sucrose and separated on 20% native polyacrylamide gels (200 V, 16 h, 4 °C). 
 
2.4.5. Maxam-Gilbert Sequencing Reaction.65 
Ten µL of [5′-32P]- and [3′-32P]-end labeled DNAs (~50000 cpm) were treated 
with 25 µL of formic acid and incubated at 25 °C for 4-5 min. The reactions were 
stopped by treatment with 200 µL of 0.3 M NaOAc, pH 7.0, 0.1 mM EDTA, and 25 
µg/mL tRNA. The resulting solutions were mixed with 700 μL of ethanol and the DNAs 
were precipitated. The DNA pellets were washed twice with 70% ethanol, and the pellets 
were resuspended in 75 µL of 10% piperidine. The reaction mixtures were incubated at 
90 °C for 30 min, and the cooled supernatants were concentrated under diminished 
pressure. The DNA pellets were washed with small amounts of water to remove residual 
piperidine and mixed with denaturing loading buffer containing 80% formamide, 2 mM 
EDTA, 1% bromophenol blue and 1% xylene cyanol. The combined solutions were 
heated at 90 oC for 10 min and used as the sequencing lanes to compare [5′-32P]-end and 
[3′-32P]-end labeled DNAs on denaturing polyacrylamide gels. 
 
2.4.6. Denaturing Gel Electrophoresis of DNA Cleavage Products.  
The [5′-32P]-end and [3′-32P]-end labeled double-strand DNA cleavage bands 
visualized by native gel electrophoresis were excised from the gels and purified by 
ethanol precipitation and then mixed with 5 μL of denaturing gel loading buffer 
containing 80% formamide, 2 mM EDTA, 1% bromophenol blue and 1% xylene cyanol. 
Following heating at 90 oC for 10 min, five-µL aliquots of the final solutions were chilled 
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on ice and separated on a 16% denaturing polyacrylamide gels containing 16% urea, 
along with 2 μL of [5′-32P]- and [3′-32P]-end labeled Maxam-Gilbert sequencing lanes to 
determine the sequences of the cleavage sites. The gels were visualized using a 
phosphorimager.  
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CHAPTER 3 
EFFECT OF ABERRANT CYTIDINE METHYLATION ON BLEOMYCIN 
INTERACTION WITH DNA 
 
3.1. Introduction 
Cytidine methylation is a key factor in epigenetic gene regulation as well as 
cancer biogenesis. Characterized by its dynamic nature,66 the methylation pattern changes 
in cancer cells and is marked by global hypo-methylation,67,68 although localized CpG-
cytidine hypermethylation has been reported in some cancers.69-74 Genomic cytidine 
hypomethylation, as related to cancer, holds the promise of additional information about 
the nature of interactions between DNA and DNA-binding therapeutic antitumor agents 
such as bleomycin. The role of bleomycin as a therapeutic agent, related to the treatment 
of cancer, has been discussed in Chapter 1.75-77 As illustrated in Chapter 2, the anti-tumor 
activity of bleomycin has been attributed to the sequence selective cleavage of DNAs and 
RNAs mediated by activated Fe•BLM.17,18,78  Although highly efficient for single strand 
cleavages, the cytotoxicity of bleomycin is largely derived from a more potent form of 
sequence specific double-strand DNA (dsDNA) cleavage.  
Recent studies involving the use of hairpin DNAs strongly bound by bleomycin 
A5 revealed that 10-20 percent of all bleomycin induced DNA cleavages can lead to 
double-strand cleavages, with an appearance at G-pyrimidine (GC or GT) sites in almost 
every reported case.54,56 As demonstrated in the literature, the reduction of bleomycin 
induced strand scission upon methylation of the substrate DNA provided a good starting 
point to understand the basis of the potency of bleomycin as a tumor cell killing 
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agent.80,81 In the present study, we employed three of those strongly bound hairpin DNAs 
(Figure 3.1) and a concentration comparable to the clinical dose of bleomycin A5 (Figure 
3.2) to study the dynamics of the interaction of bleomycin with DNA.  In addition, the 
methylated counterparts of the same DNAs were used to further study bleomycin 
mediated DNA binding and subsequent double-strand cleavage. 
 
 
Figure 3.1. 64-Nucleotide DNAs, Their Methylated Counterparts and the 16-Nucleotide 
DNA-Cf15. The red cytidine with double asterisks indicates pro-fluorescent Cf15.
79 
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Figure 3.2. Chemical Structure of Bleomycin A5. 
 
3.2.  Results 
3.2.1. Competition Assay and the Tight Binders of Fe•BLM.  
A competition assay,82 based on the inhibition of bleomycin induced cleavage of a 
16-nucleotide hairpin DNA containing a fluorescent nucleotide (Figure 3.1) at the site of 
cleavage, has been employed to measure the effect of cytidine methylation on binding 
with bleomycin quantitatively. The 16-nucleotide DNA is known to be an efficient 
substrate for bleomycin A5.
57,83 The intact 16-nucleotide DNA does not fluoresce upon 
excitation because of quenching by nucleotides within the hairpin DNA. However, when 
the DNA is cleaved by Fe•BLM, the fluorescent nucleobase is released and fluoresces 
upon being excited at 310 nm. Admixture of an equivalent of a strongly bound 64-
nucleotide hairpin DNA to the reaction mixture inhibits binding to the 16-nucleotide 
DNA and results in a proportionate decrease in fluorescence, which directly reflects the 
binding affinity of the 64-nucleotide DNA to bleomycin. 
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The main focus of this study was 64-nucleotide hairpin DNAs such as DNA 7, 
DNA 10 and DNA 11 (Figure 3.1), which have strong affinity for bleomycin, both in 
terms of binding (DNA 7 in Figure 3.3) and subsequent cleavage (DNA 7 in Figure 3.4). 
As shown in Figure 3.3, the gradual increase of the concentration of DNA 7 in the 
subsequent competition experiments involving 1 µM 16-nucleotide hairpin DNA 
significantly decreased the fluorescent peak of the 16-nucleotide hairpin DNA at 455 nm. 
At 1 µM concentration, the fluorescent peak was reduced to ~25% of the control peak. 
 
Figure 3.3. Fluorescence Emission Spectra Resulting from Treatment of 16-nt Hairpin 
DNA-Cf15 With Fe(II)•BLM in the Presence or Absence of 64-nt Hairpin DNA 7. 
Reaction mixture contained 1 µM Fe(II)•BLM, 1 µM hairpin DNA-Cf15 and 1 µM 
denatured calf thymus DNA or 0.25 µM, 0.5 µM, 0.75 µM, 1 µM and 2 µM DNA 7 in 10 
mM cacodylate buffer solution, pH 7.0, with 100 mM NaCl. The emission spectra were 
obtained following excitation at 310 nm at 25 C. 
 
In a separate experiment, the co-incubation of 1 µM random DNA with the 16-nucleotide 
hairpin DNA reduced the fluorescent peak to ~50% of the control peak, suggesting that 
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DNA 7, in comparison with the random DNA, has a stronger affinity to Fe(II)•bleomycin 
A5, which makes bleomycin less available for the binding and subsequent cleavage of the 
16-nucleotide hairpin DNA. The cleavage experiments involving radiolabeled DNA 7 
and the 16-nucleotide DNA also displayed a higher order of DNA 7 cleavage with the 
increasing concentration of random DNA (Figure 3.4). The result has been summarized 
in Figure 3.5.  
A      B 
 
 
Figure 3.4. Competition Effects of Unlabeled Denatured Calf Thymus DNA on 
Fe(II)•BLM A5 Mediated Cleavage of [5-32P]-End Labeled Hairpin DNAs 7 and 16-nt 
Hairpin DNA. (A) Lane 1, 640 μM (nucleotide concentration) radiolabeled DNA 7 alone; 
lane 2, 20 μM Fe2+; lane 3, 20 μM BLM A5; lane 4, 20 μM Fe(II)·BLM A5; lanes 5-10, 
20 μM Fe(II)·BLM A5 + 160, 320, 640, 1280, 2560, and 5120 μM (nucleotide 
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concentrations) unlabeled calf thymus DNA, respectively. (B) Lane 1, 160 μM 
(nucleotide concentration) radiolabeled 16-nt hairpin DNA alone; lane 2, 20 μM Fe2+; 
lane 3, 20 μM BLM A5; lane 4, 20 μM Fe(II)·BLM A5; lanes 5-10, 20 μM Fe(II)·BLM 
A5 + 40, 80, 160, 320, 640, and 1280 μM (nucleotide concentrations) unlabeled calf 
thymus DNA, respectively.  
 
 
Figure 3.5. Comparison of the Effects of Unlabeled Calf Thymus DNA on the Cleavage 
of [5-32P]-End Labeled Hairpin DNA 7 and 16-Nucleotide DNA by Fe(II)•BLM A5. The 
cleavage produced by Fe(II)·BLM A5 on DNA 7 and 16-nucleotide DNA in the absence 
of the 16-nt hairpin DNA was defined as 100%. 
 
In recent literature, two of the DNAs (DNA 7 and DNA 10) were also shown to 
be good substrates for bleomycin induced dsDNA cleavage.56 In this study, DNA 7-4Me 
and DNA 11-5Me were designed by replacing 4 and 5 of the cytidines by 5′-
methylcytidine; whereas DNA 10-Me had only one modification at C13, which has been 
reported as a primary site for dsDNA recognition and cleavage (Figure 3.1).56 
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Table 3.1. Inhibition of Fluorescence Emission by Hairpin DNAsa 
 
              hairpin DNA                         binding specificity (%) 
 
DNA 7                  97±1 
      DNA 7-4Me            91±2 
 
      DNA 10             85±1 
DNA 10-Me                  20±3 
 
      DNA 11                                      97±1 
DNA 11-5Me                  13±3 
 
a The binding specificity (%) was calculated as the decrease in fluorescence intensity at 
maximum emission wavelength (455 nm) from no competitor (0%) through the reaction 
mixture without Fe2+ (100%). standard erors were calculated based on three experiments 
under similar conditions.79 
 
As demonstrated in Figure 3.6, DNA 7-4Me and DNA 11-5Me containing 
methylated cytidines (Figure 3.1), on some characterized54  bleomycin cleavage sites, 
exhibited diminished binding affinity for bleomycin A5 comparing to their non-
methylated counterpart, DNA 7. Whereas the relative binding affinity of DNA 7 was 
reduced moderately from 97% to 91% upon methylation of some of its reported cleavage 
sites, DNA 11-5Me, having all of the potential cleavage sites replaced by 5-
methylcytidine, exhibited more significant reduction of binding affinity, from 97% to 
13% (Table 3.1). DNAs 7 and 11 have been shown to be strong binders of bleomycin A5 
in previous studies and both of them are known to have multiple sites of bleomycin 
cleavage including putative dsDNA cleavage sites.56 
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Figure 3.6. Fluorescence Emission Spectra of the 2-Deoxyriboside of 
4aminobenzo[g]quinazoline-2-one, Resulting from the Treatment of 16-nt Hairpin DNA 
Cf15 With Fe(II)•BLM in the Presence or Absence of 64-nt Hairpin DNAs. (A) Emission 
spectra derived from the treatment of 1 µM Fe(II)•BLM on 1 µM 16-nt hairpin DNA 
with or without 1 µM DNA 7 or DNA 7-4Me. The emission of 1 µM 16-nt hairpin DNA 
with BLM A5 was used as control. (B) Emission spectra derived from the mixture of 1 
µM Fe(II)•BLM and 1 µM 16-nt hairpin DNA with or without1 µM DNA 11 or DNA 11-
5Me. The emission of 1 µM 16-nt hairpin DNA with BLM A5 was used as control.
79 
 
The differential degree of binding affinity (Table 3.1) of DNA 7-4Me and DNA 
11-5Me is thought to be dependent on the location of the sites of cytidine methylation; 
this is further studied by the similar experiments on DNA 10, as illustrated in Figure 3.7. 
DNA 10 being a comparatively weak binder of bleomycin57 and DNA 10-Me, containing 
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only one methylated cytidine on its previously characterized dsDNA cleavage site54 
shows a dramatic change of binding affinity, from 85% to 20% (Figure 3.7). 
  
 
Figure 3.7. Emission Spectra Following Admixture of 1 µM Fe(II)•BLM and 1 µM 16-nt 
Hairpin DNA With or Without 1 µM DNA 10 or DNA 10-Me. The emission of 1 µM 16-
nt hairpin DNA with BLM A5 was used as a control and considered as 100%. The 
differences between the control, without Fe(II), and the emissions of the 16-nucleotide 
DNA in a mixture with equimolar 64-nucleotide DNAs were the measures of the relative 
binding affinity of the hairpin DNAs.79  
 
To further study the effect of cytidine methylation on bleomycin binding, another 
hairpin DNA construct, DNA 7-5Me was designed by substituting C17 of DNA 7-4Me  by 
a 5-methylcytidine and binding affinity of the DNAs were compared (Figure 3.8).  
 
 
 
 
 58 
 
Figure 3.8. Fluorescence Emission Spectra of the Profluorescent 16-nt Hairpin DNA Cf15 
With Fe(II)•BLM in the Presence or Absence of One Equivalent of a 64-nt Hairpin DNA. 
Emission spectra obtained following admixture of 1 µM 16-nt hairpin DNA with 1 µM 
Fe(II)•BLM A5 with or without 1 µM DNA 7 or DNA 7-5Me. The emission of 1 µM 16-
nt hairpin DNA following treatment with metal-free BLM A5 was used as a control. The 
emission spectra were obtained following excitation at 310 nm.79 
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Unsurprisingly, DNA 7-5Me showed reduced affinity for bleomycin binding (Table 3.2) 
compared to DNA 7 and DNA 7-4Me, which supports the hypothesis that methylation on 
cytidine gradually decreases bleomycin binding to DNA.   
 
Table 3.2. Inhibition of Fluorescent Emission by Hairpin DNAsa 
            hairpin DNA  binding specificity (%) 
 
DNA 7                  97±1 
DNA 7-5Me                  64±4 
 
DNA 9                  90±2 
DNA 9-dU                  95±1 
 
      DNA 10-Me            20±3 
DNA 10-2Me                  14±2 
DNA 10-3Me                  11±1 
 
aThe binding specificity (%) was calculated as the decrease in fluorescence intensity at 
maximum emission wavelength (455 nm) compared to the reaction having no competitor 
(0%) and the reaction mixture without Fe2+ (100%). standard erors were calculated based 
on three experiments under similar conditions.79 
 
 
 
3.2.2. DNA Methylation Results in Reduced Cleavage by Fe•BLM.  
More interestingly, when bleomycin induced DNA cleavages of 5-radiolabeled 
DNA 7 and DNA 10 was compared with their methylated counterparts an overall 
reduction of the intensity of cleavage bands was observed (Figure 3.9).  The 5-end 
labeled DNA 7, when subjected to bleomycin cleavage, resulted in seven notable 
cleavage bands, representing putative cleavage products (Figure 3.9A), similar to 
previously reported data.54 When incubated with 5 µM Fe(II)•bleomycin, the methylated 
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counterpart shows an overall reduction of the intensity of the cleavage bands, suggesting 
lower susceptibility of methylated DNAs for bleomycin induced cleavage (Figure 3.9B). 
 
 
Figure 3.9. Bleomycin Cleavage (section 3.4.5) of 5-Labeled DNA 7, DNA 7-4Me, 
DNA 10 and DNA 10-Me. (A) Sequence selective cleavage of DNA 7 by BLM A5. Lane 
1, DNA 7 alone; lane 2, 5 μM Fe(II)•BLM A5; lane 3, 10 μM Fe(II)•BLM A5; lane 4, 
G+A lane. (B) Sequence selective cleavage of DNA 7-4Me by BLM A5. lane 1, DNA 7-
4Me alone; lane 2, 5 μM Fe(II)•BLM A5; Lane 3, 10 μM Fe(II)•BLM A5; lane 4, G+A 
lane. (C) Sequence selective cleavage of DNA 10. Lane 1, DNA 10 alone; lane 2, 5 μM 
Fe(II)•BLM A5; lane 3, 10 μM Fe(II)•BLM A5; lane 4, G+A lane. (D) Sequence selective 
cleavage of DNA 10-Me. Lane 1, DNA 10-Me alone; lane 2, 5 μM Fe(II)•BLM A5; lane 
3, 10 μM Fe(II)•BLM A5; lane 4, G+A lane. The specific cleavage sites are highlighted 
on the sides of the cleavage gels.79 
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When DNAs were incubated with excess (10 µM) bleomycin, the cleavage bands 
involving sites of methylation (C15 or C13) or a site adjacent (A12) to methylated cytidines 
displayed lower intensity compared to the sites far from methylated cytidines, such as 
C17, T10 and A9. The percentage cleavage intensity at each site was measured by 
calculating the ratio of the intensity of the cleavage bands to the overall cleavage in each 
lane, represented by the summation of all cleavage bands in the individual lanes of Figure 
3.9. The summary of cleavage intensities is illustrated in Figure 3.10. Although DNA 10 
showed a reduction in cleavage intensity at the site of methylation (C13) and the 
neighboring sites such as A10 in a similar fashion (Figure 3.9C and D), more interestingly 
the cleavage at A19, a site far from C13, undergoes reduction of cleavage even when 
incubated with 5 µM bleomycin, suggesting a broader effect of methylation on bleomycin 
induced DNA cleavage, at least for some DNAs. A similar effect has been recorded when 
DNA 11 and DNA 11-5Me were subjected to 5 µM and 10 µM bleomycin A5 treatment 
for 30 minutes. DNA 11 is also a tight binder as illustrated in Figure 3.6 with several 
possible double-strand DNA cleavage sites located within the variable region of the 
hairpin DNA, two of which are sites of coupled double-strand DNA cleavages (Figure 
3.11). The overall cleavage of DNA 11-5Me, under a single hit kinetic condition, was 
diminished from 30% (DNA 11) to 17% at 5 µM Fe(II)•BLM treatment. The result is less 
dramatic at 10 µM bleomycin treatment (Figure 3.12). 
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Figure 3.10. Summary of the Cleavage Intensity at the Nucleotides in the Variable 
Region of DNA 7 and DNA 7-Me. (A) Comparison of 5 µM bleomycin A5 induced 
cleavage of nucleotides C17-A9 of DNA 7 and DNA 7-Me. (B) Comparison of 10 µM 
bleomycin A5 induced cleavage of nucleotides C17-A9 of DNA 7 and DNA 7-Me. The 
standard erors were calculated based on three experiments under similar conditions.79 
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Figure 3.11. Analysis of Fe•Bleomycin Induced Double-Strand Cleavage Sites on 
Hairpin DNA 11. (A) Double strand cleavage of [5-32P]-end labeled (lanes 1 and 2) and 
[3-32P]-end labeled (lanes 3 and 4) 64-nucleotide hairpin DNA 11 by bleomycin A5. 
Lane 1, [5-32P]-end labeled DNA alone; lane 2, 5 µM Fe(II)•BLM A5; lane 3, 5 µM 
Fe(II)BLM A5; lane 4, [3-32P]-end labeled DNA alone. (B) Sequencing gel analysis of 
bleomycin induced double-strand cleavage sites on [5-32P]-end labeled DNA 11. Each 
lane (except lanes 1) corresponds to a numbered cleavage band, shown in (A). Lane 1, 
Maxam-Gilbert G+A sequencing lane of [5-32P]-end labeled DNA 11; lane 2, band 2a; 
lane 3, band 2b; lane 4, band 2c; lane 5, band 2d; lane 6, band 2e. (C) Sequencing gel 
analysis of bleomycin induced double-strand cleavage sites on [3-32P]-end labeled DNA 
11. Each lane (except lanes 1) corresponds to a numbered cleavage band, shown in (A). 
Lane 1, Maxam-Gilbert G+A sequencing lane of [3-32P]-end labeled DNA 11; lane 2, 
band 3a; lane 3, band 3b; lane 4, band 3c; lane 5, band 3d; lane 6, band 3e. (D) Summary 
of Fe•bleomycin induced double-strand cleavage sites on hairpin DNAs 11. Orange bases 
indicate randomized region of the original hairpin DNA library. Arrows of the same 
shape and color indicate paired cleavages. Black arrows correspond to couple double- 
strand cleavage events whereas red arrows indicate non-coupled double-strand cleavage 
events, which results from two independent single-strand cleavages on opposite strands. 
Nucleotides colored in red indicate primary sites of double-strand cleavage.79 
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Figure 3.12. Bleomycin Cleavage of 5-Labeled DNA 11 and DNA 11-5Me. (A) 
Sequence Selective Cleavage of DNA 11 by BLM A5. Lane 1, DNA 11 alone; lane 2, 5 
μM Fe(II)•BLM A5; lane 3, 10 μM Fe(II)•BLM A5; lane 4, G+A lane. (B) Sequence 
selective cleavage of DNA 11-5Me by BLM A5. lane 1, DNA 11-5Me alone; lane 2, 5 
μM Fe(II)•BLM A5; Lane 3, 10 μM Fe(II)•BLM A5; lane 4, G+A lane. 
 
 
 
3.2.3. Characterization of Double-Strand Cleavage of Methylated DNAs.  
Beside the change in bleomycin-induced cleavage, it was surprising that DNA 10-
Me having a 5-methylcytidine at C13 showed a shift of bleomycin induced dsDNA 
cleavage.  As reported in a previous study, DNA 10 shows three pairs of dsDNA 
cleavages (Figure 3.13). Methylation of one of the primary sites of dsDNA cleavage 
resulted in reduced cleavage at C13-G52 with an obvious reduction of overall cleavage of 
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the DNA (Figure 3.14A). The histogram shown in Figure 3.14B illustrates that the 
percentage dsDNA cleavage at C13-G52 goes down significantly (from ~10% to ~1.5%). 
 
Figure 3.13. Summary of Fe•Bleomycin-Induced Double-Strand Cleavage Sites on 
DNAs 7, 10, and 11. Orange bases indicate randomized region of original hairpin DNA 
library. Arrows of the same shape and color indicate paired cleavages. Black arrows 
correspond to coupled double-strand cleavage events whereas red arrows indicate non-
coupled double-strand cleavage events, resulting from two independent single-strand 
cleavages on opposite strands. Nucleotides colored in red indicate primary sites of 
coupled double-strand DNA cleavage.79 
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Figure 3.14 Patterns of the Double-Strand Cleavage of DNA 10 and DNA 10-Me. (A) 
Native polyacrylamide gel representing double-strand cleavage of [5-32P]-end labeled 
(lanes 2 and 4) and [3-32P]-end labeled (lanes 1 and 3) 64-nucleotide hairpin DNA 10 
(lanes 1-2) and DNA 10M (lanes 3-4) by Fe(II)•BLM A5. (B) Histogram representing 
shift of dsDNA cleavage intensity from C13-G52 site to the neighboring sites.
79 
 
 
Two other constructs, DNA 10-2Me and DNA 10-3Me, having two and three 
cytidine substituted by 5-methylcytidine (Figure 3.15), when compared for bleomycin 
binding affinity showed a reduction of inhibition from 20% (DNA 10-Me) to 14% and 
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11%, respectively (Figure 3.16). The fluorescence inhibition data, which reflect the 
binding affinity of hairpin DNAs, are summarized in Table 3.2. Additionally, when DNA 
10-2Me and DNA 10-3Me were subjected to 5 µM bleomycin A5 treatment under single 
hit kinetic conditions, overall dsDNA cleavage was reduced to 5% and 3%, respectively 
(Figure 3.17). Compared to DNA 10-Me (Figure 3.14), hairpin DNA 10-2Me 
demonstrated an overall reduction of dsDNA cleavage of 50% with the addition of a 
methylated cytidine at C53, another putative bleomycin cleavage site. Consistent with the 
trend, DNA 10-3Me showed even less dsDNA cleavage.  
 
 
 
Figure 3.15. DNA 10 Constructs With Substitutions at C13 Alone Forming DNA 10-Me; 
C13 and C53 Forming DNA 10-2Me; C13, C11 and C53 Forming DNA 10-3Me, 
Respectively.  
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Figure 3.16. Fluorescence Emission Spectra of the Profluorescent 16-nt Hairpin DNA 
Cf15 With Fe(II)•BLM in the Presence or Absence of One Equivalent of a 64-nt Hairpin 
DNA. Emission spectra obtained following treatment of 1 µM 16-nt hairpin DNA with 1 
µM Fe(II)•BLM A5 with or without 1 µM DNA 10 and methylated variants of DNA 10,  
DNA 10-2Me and DNA 10-3Me . The emission of 1 µM 16-nt hairpin DNA following 
treatment with metal-free BLM A5 was used as a control. The emission spectra were 
obtained following excitation at 310 nm.79 
 
Table 3.3. Percentage of DNA Cleavage of Hairpin DNAsa 
 
                                         hairpin DNA  percentage cleavage (%) 
 
DNA 7                  35±3 
      DNA 7-4Me            16±2 
 
      DNA              26±4 
DNA 10-Me                  16±3 
 
DNA 11       33±3 
DNA 11-5Me                  15±4 
 
DNA 9                  20±1 
DNA 9-dU                  27±2 
 
aThe percentage cleavage for 5 µM bleomycin treatment was calculated as the ratio of the 
intensity of cleavage bands to the overall intensity of the hairpin DNA loaded in each 
well of denaturing polyacrylamide gel. standard erors were calculated based on three 
experiments under similar conditions.79  
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Figure 3.17. Patterns of the Double-Strand Cleavage of DNA 10-2Me and DNA 10-
3Me. (A) Native polyacrylamide gel showing bands resulting from double-strand 
cleavage of 5′-32P-end labeled (lanes 1 and 3) and [3-32P]-end labeled (lanes 2 and 4) 64-
nucleotide hairpin DNA 10-2Me (lanes 1 and 2) and DNA 10-3Me (lanes 3 and 4) by 5 
µM Fe(II)•BLM A5 for 1 minute. (B) Histogram illustrating the overall decrease of 
double-strand DNA cleavage intensity of C13-G52 and C13-G52 sites upon methylation of 
C53 (DNA 10-2Me) and C11 (DNA 10-3Me) in addition to C13.
79 
 
 
 
3.2.4. Structural Basis for Diminished Binding and Cleavage of DNAs Containing 
Methylated Cytidines. 
To investigate the effect of DNA methylation on BLM interaction, hairpin DNA 9 
was chosen. The DNA has two putative (5′-GT- 3) bleomycin cleavage sites. A construct 
was made with substituting T13 and T16 by deoxyuridine and the effect of bleomycin 
binding was studied by employing fluorescent inhibition assay (Figure 3.18). The 
substitution of deoxyuridine, lacking a methyl group in comparison with thymidine,  
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Figure 3.18. Fluorescence Emission Spectra of the Profluorescent 16-nt Hairpin DNA 
Cf15 With Fe(II)•BLM in the Presence or Absence of One Equivalent of a 64-nt Hairpin 
DNA. Emission spectra obtained following treatment of 1 µM 16-nt hairpin DNA with 1 
µM Fe(II)•BLM A5 with or without 1 µM DNA 9 or DNA 9-dU. The emission of 1 µM 
16-nt hairpin DNA following treatment with metal-free BLM A5 was used as a control. 
The emission spectra were obtained following excitation at 310 nm.79 
 
increased the binding affinity of bleomycin from 90% (DNA 9) to 95% (Table 3.2). This 
increased binding of bleomycin to DNA 9-dU was also reflected in Fe(II)•bleomycin 
induced cleavage of the hairpin DNA. Under the single hit kinetic condition, the overall 
cleavage of DNA 9-dU was increased to 27% from 20% in DNA 9. The increased 
cleavage and binding of DNA 9-dU was believed to be linked with the substitution of 
‘T’s in DNA 9 by deoxyuridine at the bleomycin cleavage sites (Figure 3.19 and Table 
3.3). The bleomycin cleavage of DNA 9 and DNA 9-dU was further investigated in a 
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time dependent manner at reduced temperature (0 °C), which showed the increase of 
cleavage of DNA 9-dU compared to DNA 9 (Figure 3.20). 
 
 
 
 
 
 
Figure 3.19. Sequence Selective Cleavage of DNA 9 and DNA 9-dU by BLM A5. (A) 
Lane 1, DNA 9 alone; lane 2, 1 μM Fe(II)•BLM A5; lane 3, 5 μM Fe(II)•BLM A5; lane 4, 
10 μM Fe(II)•BLM A5;  lane 5, G+A lane. (B) Lane 1, DNA 9-dU alone; lane 2, 1 μM 
Fe(II)•BLM A5; lane 3, 5 μM Fe(II)•BLM A5; lane 4, 10 μM Fe(II)•BLM A5;  lane 5, 
G+A lane. 
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Figure 3.20. Time Dependent, Sequence Selective Cleavage of DNA 9 (A) and DNA 9-
dU (B) by 5 µM BLM A5 at 0 
oC. (A) Lane 1,5 min; lane 2, 10 min; lane 3, 15 min; lane 
4, 20 min; lane 5, 25 min; lane 6, 30 min; lane 7, G+A lane. (B) Lane 1,5 min; lane 2, 10 
min; lane 3, 15 min; lane 4, 20 min; lane 5, 25 min; lane 6, 30 min; lane 7, G+A lane. (C) 
Histogram representing time dependent enhanced cleavage of DNA 9-dU.79 
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3.3. Discussion 
 Despite early evidence from the Hecht laboratory supporting the effects of DNA 
methylation on DNA cleavage by bleomycin,80,81 no systematic analysis on the effects of 
DNA methylation on DNA binding or cleavage has been reported. In this study we 
focused on factors that make DNAs amenable to high affinity binding by bleomycin 
under conditions of limited drug usage, suggesting the need to consider the role of 
naturally occurring DNA modifications. Cytidine methylation is known to affect 
nucleosome structure82 and alter gene expression, and the methylation pattern of DNA 
changes in many cancers, making it obvious to consider DNA methylation as one 
important factor influencing the action of bleomycin in a therapeutic setting.  
In recent publications, we have provided evidence suggesting that at low 
concentrations, bleomycin has a strong affinity for selected DNAs, and that these are 
likely to be bound selectively to bleomycin in a mixture of DNAs.53,57,58,83,84 Further, 
these tight binding DNAs undergo a newly characterized type of double-strand cleavage, 
which may result in double-strand gaps in duplex DNA.51,54 Given the selective targeting 
of tumor cells by BLM,34,85,86 the double-strand gaps in the genome of tumor cells may 
provide the basis for the cytotoxic effect of bleomycin. While DNA methylation within 
the human genome is abundant in both normal and cancer cells, the alteration of DNA 
methylation in cancer cells may plausibly provide additional insights into characteristics 
of the targets responsible for selective tumor cell killing by bleomycin. 
Not all cytidine methylations had the same impact on bleomycin binding to DNA. 
Methylation at a single position (C13) in DNA 10 decreases binding of Fe(II)•BLM A5 
considerably but the effect was not greatly enhanced by additional methylations at C53 
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and C11 (Table 3.2). This bis-methylated species (DNA 10-2Me) demonstrated the same 
BLM binding specificity as DNA 11-5Me with five methylated cytidines (Table 3.2). In 
contrast, DNA 7-4Me having four methylated cytidines had little effect on the binding of 
that hairpin DNA, although DNA 7 and DNA 11 exhibited similar affinities for 
Fe(II)•BLM A5 (Table 3.1). An addition of a fifth methyl group to DNA 7-4Me at a 
known site of double-strand DNA cleavage (C17, Figure 3.8 and Table 3.2) afforded DNA 
7-5Me, showed enhanced specificity of bleomycin binding. This suggested that the site of 
methylation is important for its effect on Fe•BLM binding. 
The same conclusion was reached by observing the effects of cytidine methylation 
on Fe•BLM mediated DNA cleavage of DNA 10. As shown in Figures 3.7 and 3.9, 
methylation at C13 led to an overall decrease of DNA cleavage (Table 3.3) with an 
additional shift of the observed cleavage focus to sites distant from the site of 
methylation. This implied that methylation could possibly shift the preferred site of DNA 
binding.  
There are many examples of the site selective cleavage of BLM involving both 
DNA and RNA. When excess Fe(II)•BLM is used with the combination of the B-form 
DNAs, the major cleavage sites involve 5′-GT and 5′-GC sequences,17,43 and the 5′-GPy 
sequences also appear as the primary sites of cleavage in a coupled double-strand DNA 
cleavage event.54 It is believed that Fe•BLM cleavage of DNA is preceded by binding, 
which limits cleavage to a subset of DNA and RNA sites bound effectively by Fe•BLM.85 
The relatively wide and shallow minor groove of B-form DNA at 5′-GT and 5′-GC 
sequences may plausibly favor binding by Fe•BLM. This was further supported by the 
fact that Fe•BLM cleaves the duplex domain of a DNA triplex at the junction of 5′-
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duplex-triplex, where the minor groove is wider and shallower than in canonical B-form 
DNA, as suggested by computational modeling.88 Similarly, the cleavage of transfer 
RNAs by Fe•BLM was disproportionately enhanced at the junction of single and double-
strand regions, where a structure similar to the minor groove of DNA is expected to be 
relatively wide,78 and shown to be sensitive to small changes in tRNA structure.89 
As summarized in Tables 3.1 and 3.2, cytidine methylation in hairpin DNAs 7, 10 
and 11 led to decreased Fe•BLM binding affinity and diminished DNA cleavage (Table 
3.3). Bleomycin mediated DNA cleavage is initiated with the abstraction of a hydrogen 
atom from the C4′ position of a deoxyribose sugar in the backbone of the minor groove of 
DNA. Given that the methyl group of 5-methylcytidine projects outwards from the major 
groove, the decrease of DNA binding and cleavage may not be a direct result of the steric 
interaction between the methyl group and Fe•BLM. However, it seems logical to believe 
that introduction of one or more methyl groups on the DNA major groove might 
compress the DNA minor groove to relieve the induced steric interactions, which 
ultimately affects Fe•BLM binding and cleavage in the minor groove. The reported 
decrease in flexibility in methylated DNA90-92 may also play a key role in DNA binding 
and cleavage by Fe•BLM. 
Assuming that the introduction of methyl groups in the major groove of DNA is 
the source of reduced cleavage in the DNA minor groove, it is logical to expect that the 
removal of a methyl groups might increase Fe•BLM binding and cleavage. DNA binding 
and cleavage studies involving hairpin DNAs have been carried out in DNAs having 
(per)methylated major grooves, since all of the DNAs in the original hairpin DNA library 
had thymidine residues within the randomized 8 base pair region. Hairpin DNA 9 had 
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five thymidine residues and two of which (T13 and T16) are primary sites of double-strand 
cleavage.26 Replacement of these thymidines with deoxyuridines afforded DNA 9dU, 
which augmented the binding affinity for Fe•BLM (Table 3.2) and demonstrated 
increased DNA cleavage products (Table 3.3). Even though the differences in cleavage 
involving DNAs 9 and 9-2dU were not large at room temperature, a 2-3 fold increase in 
cleavage was noted for DNA 9-2dU after 25-30 minutes at 0 oC, where the rate of  DNA 
cleavage by Fe•BLM is slower. 
The modulation of DNA minor groove width has been reported several times in 
the past,93 as a consequence of  the binding  of proteins94,95  and hairpin polyamide DNA 
binders96 to the DNA major groove. The present results offers an idea that Fe•BLM is 
sensitive to the dimensions of the minor groove to distinguish even small changes in 
geometry associated with the introduction of a methyl group to pyrimidines in the DNA 
major groove. 
In conclusion, we have demonstrated that methylation of cytidine not only 
reduces the overall cleavages mediated by bleomycin but also changes the dsDNA 
cleavage pattern. Cytidines, being a part of highly conserved CpG sequences, have direct 
involvement in epigenetic gene regulation, developmental processes and cancer 
biogenesis.97,98  
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Figure 3.21. Overall Change of the Cytidine Methylation Pattern in Cancer. Cancer is 
marked by global hypomethylation of DNA, making it more susceptible to bleomycin 
induced DNA degradation.  
 
The non-methylated and methylated hairpin DNAs used in our study 
hypothetically mimicked DNA methylation conditions observed in cancer cells. We 
demonstrated that compared to their methylated counterparts hypo-methylated DNA is 
highly susceptible to bleomycin-induced overall site-specific degradation (Figure 3.9) 
and dsDNA cleavages (Figure 3.14). This suggests an increased lethal effect of 
bleomycin in cancer cells. Bleomycin, which has been reported to be a minor groove 
binder,99 also shows a variable degree of reduction of binding to the methylated DNAs as 
a result of the possible local structural change due to methylation.100 The compromised 
binding and subsequent reduction of cleavage induced by bleomycin may be derived 
from the local pinching of the minor groove, without disrupting the overall structure of 
DNA at the site of methylation.101,102 
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Summarizing our findings in Figure 3.20, we posit that the potency of bleomycin 
as an antitumor agent is affected by DNA methylation, providing a model to explain its 
possible enhanced binding and degradation of DNA in cancer cells. 
 
3.4.  Experimental 
3.4.1. Materials.  
T4 polynucleotide kinase was purchased from New England Biolabs. 
Recombinant terminal deoxynucleotidyl transferase was obtained from Roche Applied 
Science. Radiolabeled nucleotides [γ-32P]-ATP and [α-32P]-cordycepin were purchased 
from Perkin Elmer Life Sciences. Fe(NH4)2(SO4)2•6H2O  and Chelex 100 were from 
Sigma Aldrich. All the synthetic oligonucleotides including the hairpin DNAs were 
obtained from Integrated DNA Technologies, Inc. The 16-nucleotide hairpin DNA-Cf15 
was purchased from Chemgenes using nucleotide analogue Cf15 synthesized by M. P. 
Alam. The 64 nucleotide hairpin DNA 11 was obtained from Chenhong Tang through a 
rigorous selection process with the goal of obtaining hairpin DNAs tightly bound to 
Fe(III)•BLM A5. 
 
3.4.2. End Labeling and Purification of Hairpin DNAs and Their Methylated 
Counterparts.  
The hairpin DNAs were 32P-end labeled using a combination of [γ-32P]-ATP and 
T4 polynucleotide kinase or [α-32P]-cordycepin and terminal deoxytransferase at the 5′ 
and 3′-ends, respectively. Ten pmol of 64-nucleotide hairpin DNAs were [5ʹ-32P]-end 
labeled by incubation with 20 units of T4 polynucleotide kinase and 0.06 mCi [γ-32P]-
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ATP (specific activity 6000 Ci (222 TBq)/mmol) in 50 μL (total volume) of 70 mM Tris-
HCl buffer, pH 7.6, containing 10 mM MgCl2 and 5 mM DTT. The reaction mixture was 
incubated at 37 °C for 1 h followed by DNA purification by 16% polyacrylamide gel 
electrophoresis at 1800 V for 2.5 h. The [3ʹ-32P]-end labeling was done by incubating 10 
pmol of hairpin DNA with 20 units of terminal deoxynucleotidyl transferase and 0.06 
mCi [α-32P]-ATP (specific activity 6000 Ci (222 TBq)/mmol) in 50 μL (total volume) of 
70 mM Tris-HCl buffer, pH 7.6, containing 10 mM MgCl2, 10 mM CoCl2 and 5 mM 
DTT. The reaction mixture was incubated at 37 °C for 1 h followed by purification of 
DNA by 16% polyacrylamide gel electrophoresis at 1800 V for 2.5 h. 
 
3.4.3. Double-Strand DNA Cleavage of Hairpin DNA 10, 10-Me, 10-2Me and 10-
3Me.  
Bleomycin cleavage of 5ʹ and 3ʹ-end labeled hairpin DNAs was performed by 
incubating the hairpin DNA (~30000 cpm) with 5 μM Fe2+ and 5 μM bleomycin A5 at 25 
°C for 30 min in a 10 µL 10 mM Na cacodylate, pH 7.0 solution containing 2 mM 
MgCl2. Two μL of native gel loading buffer containing 0.25% bromophenol blue, 0.25% 
xylene cyanol and 40% D-sucrose were added to the reaction mixture, which was 
separated on a 20% native polyacrylamide gel (200 V, 16 h, 4 °C ). Double-strand 
cleavage sites were identified by visualizing co-migrating bands, using a 
phosphorimager. 
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3.4.4. Maxam-Gilbert Sequencing Reaction.65 
Ten µL of 5ʹ and 3ʹ-end labeled DNAs (~50000 cpm) were incubated with 25 µL 
of formic acid at 25 °C for 5 min. The reactions were mixed with 200 µL of 0.3 M 
sodium acetate, 0.1 mM EDTA, and 25 µg/mL E. coli tRNA. The resulting solutions 
were immediately mixed with 700 µL ethanol to precipitate the DNAs. The DNA pellets 
were washed twice with 70% ethanol, and the pellets were resuspended in 75 µL of 10% 
piperidine. The reaction mixtures were incubated at 90 °C for 30 min and then chilled on 
ice. The cooled supernatants were concentrated under diminished pressure. The DNA 
pellets were washed with small amounts of water to remove residual piperidine and 
mixed with denaturing loading buffer containing 80% formamide, 2 mM EDTA, 1% 
bromophenol blue and 1% xylene cyanol. The combined solutions were heated at 90 °C 
for 10 min and used as the sequencing lanes to compare [5-32P]-end and [3-32P]-end 
labeled DNAs on denaturing polyacrylamide gels. 
 
3.4.5. Sequence-Selective Cleavage of Radiolabeled Hairpin DNAs by BLM A5.  
[5-32P]-end-labeled hairpin DNA 7, DNA 7-Me, DNA 10 and DNA 10-Me 
(~50000 cpm) were incubated with 5 µM or 10 µM FeBLM A5 in a 5 µL reaction, 
containing 10 mM Na cacodylate buffer, pH 7.0, for 30 min. Five µL of denaturing gel 
loading buffer containing 98% formamide, 2 mM EDTA, 0.25% (w/v) bromophenol 
blue, and 0.25% (w/v) xylene cyanol were added to the reaction mixture. The resulting 
solutions were heated at 90 °C for 10 min followed by chilling on ice. Five µL of each 
sample was loaded onto a denaturing gel (16% polyacrylamide and 7 M urea) along with 
2 μL of 5-32P and [3-32P]-end labeled Maxam-Gilbert sequencing lanes to determine the 
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sequences of the cleavage sites. The gels were run at 50 W for 2.5 h. The gels were 
visualized using a phosphorimager. 
 
3.4.6. Fluorescence Competition Analysis of Hairpin DNAs.  
Five µM 64- nucleotide hairpin DNA solutions were incubated with 5 µM 
bleomycin A5 in 10 mM sodium cacodylate buffer solution, pH 7.0, at room temperature 
for 20 min. The resulting solution was mixed with equimolar 16-nucleotide hairpin DNA 
having Cf at cytidine15 (hairpin DNA-Cf15) and incubated at room temperature for 1 min. 
Freshly prepared Fe(NH4)2(SO4)4 was added to the solution to a final concentration of 1 
µM. In the final solution 16-nucleotide hairpin DNA, 64-nucleotide hairpin DNAs, 
bleomycin and Fe2+ were all present at 1 µM concentration. The solution was maintained 
at room temperature for 30 min. The same volume of buffer solution was added to the 
control sample without Fe2+ and 64-nucleotide hairpin DNA.  The fluorescence emission 
was measured at 25 °C. The samples were excited at 310 nm, and the emission signal was 
collected from 400 to 550 nm using an excitation slit width of 10 nm and an emission slit 
width of 10 nm. 
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CHAPTER 4 
EVALUATION OF THE INTERACTION BETWEEN BCL2 PROMOTER ELEMENT 
AND INDIVIDUAL DOMAINS OF hnRNP LL, LEADING TO A STRUCTURAL 
CHANGE IN DNA 
 
4.1. Introduction 
DNA secondary structures are known to play important roles in complex cellular 
processes.102 Studies have shown that the presence of secondary structures is fairly 
common in functionally important regions in the genome. One such widely studied 
secondary structure is the G-quadruplex, which is found in several promoter sites,103 5 
UTRs104 and telomeric regions.105 Similar to G-quadruplexes, another interesting DNA 
structural eliment is the cytidine rich i-motif. Unlike the G-quadruplex, the i-motif 
structure is highly flexible and several factors such as pH and heat can play vital roles in 
folding of DNA, leading to specific i-motif structures.106 Analogous to their structural 
counterpart G-quadruplexes, i-motifs are also abundant in the promoter regions of certain 
genes.107,108 One of such important gene is BCL2 (B-cell lymphoma gene-2).  
The product of the BCL2 gene is an anti-apoptotic protein, classified as an 
oncogene. Overexpression of the BCL2 gene prolongs cell survival, linking it to the 
development of cancer.109,110 Previous studies have demonstrated that the C-rich 
upstream promoter region of BCL2 forms a highly dynamic i-motif structure,106 which 
can act as an transcriptional switch for the expression of the BCL2 gene.112,113 Recent 
findings further reveal that the BCL2 i-motif can be a potential target for  small molecules 
and, more interestingly, for transcription factors such as hnRNP LL.113  
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Figure 4.1. Sequence of hnRNP LL With Four Interactive Domains. 
 
The hnRNP LL, homologous to hnRNP L with more than 50% sequence 
similarity in certain species, belongs to a class of small RNA binding proteins. Unlike 
hnRNP L and other proteins of that family, the structure of hnRNP LL has not been fully 
characterized. It is known that the protein has four functional domains, RRM1-4. Among 
these domains, RRM1 and RRM2  are separated by a short sequence of amino acids, 
whereas domains 3 and 4 are connected by a linker region (Figure 4.1). According to the 
hypothesis set forth in previous studies, two of the hnRNP domains (RRM1 and RRM2) 
are more likely to recognize and bind the BCL2 i-motif, and RRM3 and RRM4 could 
possibly play an important role in unwinding and stabilizing the downstream i-motif 
structural changes and engaging other factors to initiate transcription (Figure 4.2).113 In 
this study, we focused on the specific interactions of the domains of hnRNP LL and the 
BCL2 i-motif DNA, which may give us insights into the biological role of structurally 
complex DNAs. More specifically, understanding the interaction of BCL2 promoter and 
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transcription factors such as hnRNP LL could reveal the pattern of BCL2 gene regulation 
and help us to design peptides or peptide mimics  to target complex DNA regions.  
 
Figure 4.2. BCL2 Promoter i-Motif Sequence and Structures of Individual Domains of 
hnRNP LL. (A) Interchangeable i-motif and hairpin structure of BCL2 promoter element. 
(B) Proposed mechanism of BCL2 gene regulation by the interaction of Complex i-motif 
structure and transcription factor hnRNP LL. The binding interaction of hnRNP-LL 
domains with i-motif unfolds the complex structure and facilitates the downstream 
transcription. 
 
 
 
4.2.  Results 
4.2.1. RRM Constructs.  
To understand the individual interactions of the four domains of hnRNP LL and 
the BCL2 i-motif, the domains were cloned in pET 28a vectors and expressed separately 
using E. coli BL21-DE3 cells. Domains RRM1 or RRM2, and RRM3-4, were constructed 
with an additional 15 to 20 amino acids on both the C and N termini of the construct, 
flanking the sequence optimized for expression in E. coli (Figure 4.1). The genes were 
equipped with a Strep-tag at the C-terminus for streptactin mediated protein purification. 
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The domain structures as illustrated in Figure 4.3 were determined by sequence 
homology interpretation based on other well characterized homologous proteins of the 
family. 
 
Figure 4.3. Predicted Structures of RRM1, RRM2 and RRM3-4 Based on Sequence H-
Homology With Other Members of That Protein Family. 
 
The three-dimensional structure of RRM1 was modeled with reference to the solution 
structure of N-terminus mouse protein BAB28521 (PDB ID: 1WEX). Similarly, the 
structure of RRM2 was predicted in reference with the solution structure of mouse 
hnRNP LL RRM2 (PDB ID: 2E5I), whereas RRM3-4 was modeled based on the crystal 
structure of human hnRNP L (PDB ID: 3TO8). 
 
4.2.2. Study of the Binding Interaction Between Domains and i-Motif. 
The binding interactions between each of the three constructs containing the four 
domains of hnRNP LL and the i-motif were studied by employing a gel shift assay. As 
postulated in previous studies, RRM1 and RRM2 showed strong binding to the DNA 
(Figure 4.4A and B) when the DNA to hnRNP LL domains molar ratio was varied from 1 
to 8 equivalents. Furthermore, both domains were shown to interact with the i-motif 
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DNA with varying affinities. The histograms in Figure 4.4C and D illustrate that at 8 
molar equivalents concentration both the domains bind to DNA to the extent of >50%, 
when incubated at room temperature (Table 4.1). Interestingly, RRM3-4 (Figure 4.1) 
appeared to be a weak binder of the i-motif DNA (Figure 4.5 and Table 4.2). Varying 
concentrations of RRM3-4 (2.5 to 100 molar equivalents), when incubated with 1 
equivalent of i-motif, showed less than 50% binding, even using 25 equivalents of the 
RRM domains. The gel reveals the presence of two protein ̶ DNA complexes, labeled as 
complex 1 and complex 2 (Figure 4.5A), suggesting a more complex interaction between 
domain 3-4 of hnRNP LL and the i-motif.  
 
Figure 4.4. Binding Interaction Study of RRM1, RRM2 and i-Motif DNA. (A & B) 
binding of RRM2 and RRM1 (1, 2, 4 and 8 molar eq.) with i-motif DNA, respectively. (C 
& D) Histogram showing percentage of DNA ̶ protein complex formation with varying 
concentrations of RRM2 and RRM1, respectively. The Y-axes indicate percentage DNA 
binding with hnRNP domains. 
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Table 4.1. Percentage Binding of i-Motif by RRM1 and RRM2a 
 
RRM1 RRM2 
eq. of protein to DNA % binding eq. of protein to DNA % binding 
0 0 0 0 
1 0 1 0 
2 8 2 1 
4 43 4 75 
8 73 8 88 
    
    
a The percentage binding of protein and DNA was calculated as the percentage intensity 
of the protein ̶ DNA complex band relative to the total DNA in each lane. 
 
In addition, both of the domains were shown to have a stronger affinity toward the i-motif 
DNA compared to calf thymus DNAs. The specificity of the binding interaction was 
studied with varying concentrations of calf thymus DNA (0.25 to 1 molar equivalent) in 
mixture with one equivalent of i-motif DNA and domains 1 or 2 
 
 
 
 
Figure 4.5. Binding Affinity Study of RRM3-4 and i-motif DNA. (A) binding affinity of 
RRM3-4 (2.5, 5, 10, 20, 25, 50 and 100 molar eq.) for i-motif DNA. (B) Histogram 
showing percentage of DNA-protein complex formation with a varying concentration of 
RRM3-4. 
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 (Figure 4.6A and B). In the presence of the equivalent concentration of a random 
competitor, both of the domains showed more than 50% binding interaction when 
incubated with equimolar substrate, i-motif DNA (Figure 4.6C, D and Table 4.3). 
 
Table 4.2. Percentage Binding of i-Motif by RRM3-4a 
 
eq. of RRM3-4 % to total i-motif 
to i-motif unbound complex 1  complex 2 
0 98 2 2 
2.5 98 2 2 
5 97 2 1 
10 96 2 2 
20 91 7 2 
25 55 25 20 
50 40 38 22 
100 39 31 30 
    
a The percentage complex formation between protein domain and i-motif was calculated 
as the percentage intensity of the bands indicating complex formation relative to the total 
DNA in each lane. 
 
 
 
4.2.3. Structural Change of i-Motif Following the Binding With RRMs. 
Previous investigations suggested that the interaction between the domains and 
the i-motif is likely to unwind the complex secondary structure, which may result in 
transcription initiation from the promoter region of the BCL2 gene.113 In this study, the 
structural change of BCL2 i-motif has been studied while interacting with the domains of 
hnRNP LL, such as RRM1 and RRM2, by employing a bromine-footprinting technique 
(section 4.4.4). As observed in Figure 4.7, the i-motif DNA shows a differential rate of 
bromination on cytidine nucleotides in the SII and SIII regions of i-motif, followed by 
cleavage of DNA at brominated nucleotides. The variation of the extent of bromination is 
attributed to the complex structure of the i-motif, which restricts the accessibility of 
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cytidine for bromination. The i-motif shows unwinding of the complex structure at higher 
pH, with a transition pH at 6.6.113 It is evident from Figure 4.7 that when i-motif DNA 
was treated with RRM1 and RRM2 at pH 6.6, the accessibility of nucleotides for 
bromination changed  
 
Figure 4.6. Gel Shift Competition Assay Revealing the Binding Specificity of RRM1 and 
RRM2 for i-Motif DNA. (A & B) RRM2 and RRM1 binding competition with i-motif 
and varying concentration (0.25, 0.5 and 1 molar eq.) of random Calf thymus DNA, 
respectively. (C & D) Histogram representing percentage of DNA ̶ protein complex 
formation while radiolabeled i-motif and a varying concentration of random calf thymus 
DNA was incubated with RRM2 and RRM1, respectively.  
 
dramatically, suggesting the conversion of the i-motif structure to a less complex DNA 
structure. A similar experiment done at pH 7.0 (Fig 4.8), which has a higher 
concentration of linear DNA, does not show any evidence of a further change in 
structure. 
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Table 4.3. Percentage Binding of i-Motif by Domains With Varying Random DNAa 
 
RRM1 RRM2 
eq. of 
protein 
eq. of random 
DNA 
% 
binding 
eq. of 
protein 
eq. of random 
DNA 
% 
binding 
0 0 2 0 0 1 
10 0 90 10 0 98 
10 0.25 82 10 0.25 93 
10 0.5 80 10 0.5 84 
10 1 69 10 1 81 
 
 
a The percentage binding of protein and DNA was calculated as the percentage intensity 
of the protein-DNA complex band to the total DNA in each lane. 
 
 
Figure 4.7. Analysis of Structural Change in BCL2 i-Motif as a Result of Binding With 
RRM1 and RRM2. (A) structural change of i-motif observed in bromine footprinting 
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assay at pH 6.6. Lane 1, Maxam ̶ Gilbert G+A lane; lane 2, DNA alone; lane3, DNA + 
RRM1; lane 4, DNA + RRM2. (B) i-motif structure showing C-rich SII, SIII and loop 
L3, which shows significant changes upon bromine-footprinting assay. 
 
The summary of the susceptibility of nucleotides, spanning C27 to C15, to Br2 
induced cleavages, upon incubation with RRM1 and RRM2 at pH 6.6, reveals that stems 
2 and 3 of the i-motif become more accessible to bromine, after the binding of the hnRNP 
LL domains, which results in at least partial relaxation of the complex i-motif structure 
(Figure 4.9).   
 
 
 
Figure 4.8. Br Footprinting of i-Motif in the Presence or Absence of RRM1 and RRM2 
at pH 7.5. Lane 1, Maxam ̶ Gilbert G+A lane; lane 2, DNA alone; lane3, DNA + RRM1; 
lane 4, DNA + RRM2; lane 5, DNA alone. 
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The i-motif structural change was studied by analyzing the CD spectra of the 
DNA in the presence of RRM1 and RRM2 (Figure 4.10). As noted previously, the BCL2 
i-motif has a characteristic CD spectrum with a distinct peak at 286 nm.113 This peak 
decreases when the CD spectrum is monitored at higher pH, compared to a more acidic 
pH, suggesting a shift of equilibrium between two or more forms of the i-motif (Figure 
4.2). As established in previous studies, the complex i-motif structure exists 
predominantly at lower pH, and decreases gradually with an increase in pH.110 As shown 
in Figure 4.10, the peak at 286 nm is decreased with the addition of RRM1 and RRM2, 
which suggests a significant structural change of i-motif when it interacts with the 
specific domains of the protein.  
 
Figure 4.9. Histogram Resulting from Bromine Footprinting Assay Represents Structural 
Changes in the Region Between C27 to C15, Encompassing C-Rich SII, SIII and Loop L3 
of i-Motif Due to the Binding Interaction With RRM1 and RRM2. The individual lines 
represents the trend of radioactive intensity of the cleavage bands at each nucleotides in 
SII, SIII and L3 regions of i-motif. The Y-axis indicates the absolute intensity of the 
cleavage bands as directly related to the availability of the individual nucleotides for 
bromination. 
 
The change in the CD spectrum was less prominent when the spectral analysis of the 
hnRNP LL domains and the i-motif interaction was examined at higher pH, such as pH 
7.5 (Figure 4.11). The lower reduction of the peak is attributed to the absence of the i-
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motif structure, which is replaced by the unstructured DNA at higher pH, as suggested in 
earlier literature.113 
 
Figure 4.10. CD Spectra of i-Motif With Various Concentrations of RRM1 and RRM2, 
Suggesting Structural Change Upon Binding. (A) CD spectra of i-motif DNA at pH 6.6 
with varying concentrations of RRM1. (B) CD spectra of i-motif DNA at pH 6.6 with 
varying concentrations of RRM2. 
 
 
 
4.2.4. Sequence Based Binding Between i-motif and RRMs. 
A computer simulation based on homologous protein hnRNP L, predicted the 
amino acids in RRM1 which may take part in substrate (i-motif) binding. A thorough 
binding interaction study and kinetic analysis was envisioned, employing the FRET 
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technique. In previous studies, the lateral loops 1 and 2 of the i-motif DNA (Figure 4.2) 
were found to interact with RRM1 and RRM2.113 In order to determine which region of  
the i-motif interacts with RRM1 and RRM2, several modified i-motif DNAs were 
synthesized (Figure 4.12) and their binding interactions with RRM1 and RRM2 were 
studied (Figure 4.13).  
 
 
Figure 4.11. CD Spectra of i-Motif and RRM1 (A), RRM2 (B) Interaction at pH 7.5. 
 
The CD spectra of the modified i-motifs reveals that a point mutation in the C-
rich i-motif stem did not alter the equilibrium between the i-motif structures, which is 
evident in a small reduction of the i-motif peak at 286 (Figure 4.12A). Interestingly, the 
mutations in the loop structures of the DNA reveal that the nucleotide sequences of the 
L1 and L2 loops are essential for i-motif structure whereas loop L3 plays a less important 
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role in the stabilization of the i-motif (Figure 4.12B). As observed in Figure 4.13, the 
mutations in loop structure decrease the binding of the i-motif to protein, whereas 
structural changes, as a result of the point mutations, in the C-rich region of the i-motif 
did not effectively change the binding interaction. This suggests, in full agreement with 
the previous report,113 that the lateral loops flanking the C rich i-motif structures are 
important for RRM1 and RRM2 binding.   
 
 
 
Figure 4.12. Circular Dichroism Analysis of BCL2 i-Motif Mutants. (A & B) Change in 
CD spectra of BCL2 i-motif stem and loop mutants, respectively. (C) Table illustrating 
sequences of the i-motif mutants used in the binding study.  
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Figure 4.13. Binding Interaction Study of BCL2 i-Motif DNA Mutants With hnRNP LL 
RRM1 and RRM2. (A & B) Binding affinity of RRM1 and RRM2 to five of  the BCL2 i-
motifs with specific modification at the C-rich region and four of the modified BCL2 i-
motif mutants with specific modifications at loops flanking the C-rich region, 
respectively . lane 17, BCL2-i_35T and 10 equivalents of RRM1; lane 18, BCL2-i_5T 
and 10 equivalent of RRM2. (C) Histogram representing percentage formation of RRM1, 
RRM2 and i-motif mutant complexes. 
 
 
 
4.2.5. FRET between i-Motif and RRM1. 
The interaction of RRMs and the i-motif was further investigated by studying 
FRET between an amino acid donor in the RRMs and a nucleotide acceptor into i-motif. 
Several constructs were made using site-directed mutagenesis, at different positions of 
the RRM1 sequence (Figure 4.14B), to convert native amino acid residues into amber 
codons. Plasmids containing an amber codon were subjected to in vitro protein synthesis, 
with modified tRNA charged with a 6-cyanotryptophan (Figure 4.14A), which afforded 
the modified constructs with incorporation of cyanotryptophan, as a fluorescent donor 
molecule, in different positions of RRM1, including Y137, Y147 and Y104. Purified 
proteins were used in FRET analysis with i-motif modified at the L3 central loop 
(BCL2i-22C) with a cytidine analogue (Figure 4.14A) as an acceptor, and the distance 
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between donor and acceptor was calculated from a FRET efficiency measurement, as 
outlined in section 4.4.14.  
 
 
 
Figure 4.14. FRET Experiment With Amino Acid Substitution at Three Different 
Positions of RRM1. (A) Donor and acceptor molecules. (B) The tyrosines resedues in 
RRM1 were alternatively substituted by 6-cyanotryptophan in three different constructs. 
 
RRM1-137-CTP was synthesized by employing the in vitro protein synthesis 
method, using tRNACUA charged with 6-cyanotryptophan (CTP) and a plasmid containing 
RRM1 coding region with an amber codon at tyrosine 137 (Y137). Five µM RRM1-137-
CTP was excited at 310 nm (excitation slit width = 10 nm) and titrated with BCLi-22C 
up to 200 nM DNA, ensuring maximum binding. Emission (emission slit width = 10 nm) 
was monitored from 325 nm to 550 nm (Figure 4.15A). A similar experiment with 20 µM 
RRM1-wt and 200 nM BCL2i-22C was performed with no observable increment of 
emission peak of the acceptor at 440 nm (Figure 4.15B). Similarly RRM1-147-CTP and 
RRM1-104-CTP were synthesized by in vitro protein synthesis with plasmids containing 
an amber codon at tyrosine 147 (Y147) and tyrosine 104 (Y104), respectively. FRET 
 98 
experiments with these proteins and BCL2i-22C showed significant energy transfer 
between donor and acceptor only when the donor was placed at Y104 (Figure 4.16B).  
 
 
 
Figure 4.15: FRET Between RRM1-137-CTP and BCL2i-22C at 310 nm Excitation. (A) 
RRM1-137-CTP. (B) Wild type protein highlighted in purple line shows no significant 
FRET. 
 
The interaction between RRM1 and the i-motif was simulated using docking tools 
affording numerous possible binding solutions. Exemplified in Figure 4.17A, a model 
oligonucleotide (CCCCA) was used as the substrate for RRM1. The distance between a 
donor (amino acid analogue) and acceptors (nucleotide substituents) can be measured 
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based on the location information available for the acceptors. In Figure 4.17B, three of 
the best fitting RRM1-oligomer binding solutions are reported, assuming that the donor is 
Y104 and that the acceptors are located on both termini of the DNA. Comparison of the 
simulation derived distances with the experimentally determined distance between the 
donor and acceptor supports the potential of this method to afford reasonably accurate  
 
 
Figure 4.16: FRET Between (A) RRM1-147-CTP, (B) RRM1-104-CTP and BCL2i-22C 
at 310 nm Excitation. 
 
molecular prediction of binding. A more realistic and detailed analysis is possible when 
the FRET experiments are carried out with donors at different locations resulting from 
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position-based amino acid substitutions (Figure 4.14), under a variety of experimental 
conditions. The FRET efficiency between the donor at Y137 and Y104 and acceptor in 
the i-motif was calculated following the method described in the experimental section. 
The FRET efficiency between the donor and acceptor from the RRM1-137-CTP / i-motif 
pair was 0.300.03. Similarly, the FRET efficiency between the donor and acceptor from 
RRM1-104-CTP / i-motif pair was 0.120.01. From the FRET efficiency, the distance 
between donor and acceptor was also calculated (36.00.7 Å when the donor was at 
Y104, and 29.80.6 Å when the donor was placed at Y137) and the information was used 
for the simulation of i-motif and RRM1 interaction an unambiguous distance restraint, 
using the Haddock web-server modeling tool (Figure 4.18).114-116 
 
 
Figure 4.17. Simulation of the Interaction Between Oligonucleotide CCCCA and RRM1. 
(A) Simulation of possible RRM-ssDNA interaction. (B) Locations of the amino acid 
donor at Y104 and nucleotide acceptors placed at the 5 (A, B and C) or 3-termini (a, b 
or c) of the DNA in three different models. 
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4.3.  Discussion 
In this study BCL2 i-motif DNA has been shown to interact with at least two of 
the individual domains of hnRNP LL (Figure 4.4). The binding interaction also imposed 
considerable change in the structure of the BCL2 i-motif (Figures 4.7 and 4.10). As 
shown in Figure 4.4 domains 1 and 2 bind to i-motif DNA with higher affinity, in 
comparison with RRM3-4. A comparative study (Figure 4.4C and D) suggests that 
RRM2 may have a higher affinity of binding to the i-motif than RRM1, analogous to 
domains 2 and 1 of hnRNP L, respectively. Interestingly, domain 2 of hnRNP L has also 
been reported to have higher binding affinity toward specific RNA substrates in previous 
studies.117  In a combination of the i-motif DNA mixed with calf thymus DNA (Figure 
4.5A and B), RRM1 and RRM2 showed a moderately higher binding affinity for the i-
motif DNA. Both domains bind selectively to the i-motif when incubated with an 
equimolar mixture of i-motif and random DNA, suggesting the existence of a potential 
recognition motif within the oligonucleotide sequence of the i-motif. 
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Figure 4.18. Haddock Modeling Tool Derived Binding Simulation of RRM1 and BCL2i-
22C. The nucleotides and substituted amino acid are shown in red. The modeling solution 
was visualized by PyMOL. 
 
In previous studies, it was proposed that binding of the i-motif with hnRNP LL 
leads to a significant structural change in the i-motif,113 which in turn initiates the process 
of downstream transcription of the gene. The uniform banding pattern of the i-motif DNA 
using bromine footprinting analysis at pH 7.5 (lanes 2 and 5 in Figure 4.8) suggests that 
the DNA is already in a less structured form, supporting the previous finding that at 
BCL2 i-motif DNA exhibits the structure at lower pH.  The transition pH for the 
oligonucleotide to undergo a structural change from the complex i-motif to a simpler 
form has been reported to be pH 6.6.113 Incubation of the i-motif with either RRM1 or 
RRM2 (lanes 3 and 4 in Figure 4.8) at pH 7.5 did not change the structure further. In cells 
the i-motif is found in the promoter region of the oncogene, which encodes the protein 
Bcl-2. In a cellular environment the promoter may retain the complex i-motif structure in 
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a locally favorable acidic environment. The C-rich region of the promoter has been also 
reported to bind to transcription factors, undergoing structural changes and facilitating 
transcription. In our study, when the i-motif was subjected to bromine footprinting assay 
at pH 6.6 it showed a non-continuous cleavage band pattern in the denaturing gel (Figure 
4.7A, lane 2), suggesting that most of the cytidines in the oligonucleotide sequence are 
taking part in forming an i-motif structure as confirmed in previous studies.113 
Intriguingly, when incubated with RRM1 and RRM2, the cytidines were shown to be 
more available for bromination and subsequent cleavage by pyridine, which suggests that 
the binding resulted in a structural change of the DNA, from a more complex i-motif  to a 
simpler linearized DNA (Figure 4.7A, lanes 3 and 4). In a cellular environment, this 
phenomenon may lead to the initiation of downstream transcriptional processes (Figure 
4.19).  
 
Figure 4.19. Proposed Mechanism of RRM1 and RRM2 Interaction With i-motif DNA 
and Subsequent Unfolding of the Complex Structure. Both the domains of hnRNP LL 
were postulated to interact with the lateral loops L1 and L2 of i-motif to initiate 
relaxation of the complex stem ̶ loop structure of the oligonucleotide. 
 
The structural change of the i-motif was studied by obtaining CD spectra of the 
combination of oligonucleotide and the domains of hnRNP LL at pH 6.6. As evident in 
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both Figures 4.10 and 4.11, the structure of the i-motif changes greatly as a result of the 
interaction with RRM1 and RRM2. In both Figures (4.10 and 4.11), the observed 
decrease of the characteristic i-motif peak at 286 nm with increasing concentration of 
protein suggested that the i-motif structure may have been gradually converted to a linear 
DNA upon binding. The increasing area within the negative peak at 210 nm is 
characteristic of protein domains, which was consistent with the increase in protein 
concentration in subsequent experimental steps. In Figure 4.10B, the structural change of 
the i-motif is more prominent, which is represented by the blue line (5 molar equivalents 
of RRM2), indicating the strong binding interaction of RRM2 with the i-motif DNA, 
ultimately resulting in a shift of the 286 nm peak to 270 nm. 
A thorough binding assay employing modifications of the i-motif DNA (Figure 
4.12C) with the RRMs revealed that the specific interaction of hnRNP LL domains with 
the i-motif is more dependent on the loop sequences and less likely depends on the 
specific structure of the DNA (Figure 4.13B). The complex C-rich region of i-motif may 
not interact with the domains and in fact, subtle changes in the i-motif structures (Figure 
4.12A) do not affect binding. In accordance with the previous studies,113 it was confirmed 
that the domains bind to the loops of the i-motif DNA and may have little interaction with 
the C-rich region (Figure 4.19).  
To further extend our knowledge of i-motif and RRM1 interaction, the FRET 
technique has been utilized with i-motif DNA and the domains of hnRNP LL. Based on 
the binding interaction study, a nucleotide in the region of the central loop (19 to 24) was 
replaced by a synthetic nucleotide analogue, which can serve as an energy acceptor in the 
FRET experiments. Replacement of the cytidine nucleotide with a fluorescent analogue 
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of cytidine (Figure 4.14) afforded BCL2i-22C. Similarly, replacing a tyrosine (Y137, 
Y147 and Y104) by a synthetic unnatural amino acid analogue provided the FRET donor. 
FRET efficiencies between the donors at positions 137 and 104 and the acceptor at a 
fixed position in BCL2i-22C were calculated using the method described in section 
4.4.15, which also afforded the calculation of the distances between Y137 or Y104 and 
the cytidine nucleotide of the BCL2 i-motif, while bound to the protein. The FRET 
efficiency between the donor at position Y147 and BCL2i-22C with the acceptor at C22 
was exceptionally low (<10%), hence not used for further distance calculation to avoid a 
higher order of error. The FRET efficiency and the distance calculations were performed 
using a simplified method without involving the corrections for the donor and acceptor 
environments, which will be subjected to further speculations involving additional 
experiments. The distances involving Y137 and Y104 were used in the Haddock 
webserver based simulations114-116 to gain more insight into RRM1 ̶ BCL2 i-motif binding 
interaction, as illustrated in Figure 4.20. 
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Figure 4.20. Modeling of RRM1 and i-Motif Interaction With or Without Using FRET 
Derived Distance Information. (A) Rigid body docking without using an unambiguous 
restraint. (B) Flexible docking of RRM1 and the i-motif DNA, which was based on 
modeling involving a flexible DNA backbone and experiment derived distances between 
specific amino acids and the nucleotide, C22 as unambiguous restraints. 
 
 
 
4.4.  Experimental  
4.4.1. End-labeling of Oligonucleotides 
BCL2 i-motif was [5-32P]-end labeled with -32P ATP + T4 polynucleotide kinase 
enzyme. Ten pmol of DNA was 5-32P end labeled by incubation with 20 units of T4 
polynucleotide kinase and 0.06 mCi [γ-32P]ATP (specific activity 6000 Ci (222 
TBq)/mmol) in 50 μL (total volume) of 70 mM Tris-HCl buffer, pH 7.6, containing 10 
mM MgCl2 and 5 mM DTT. The reaction mixture was incubated at 37 °C for 1 h 
followed by purification of DNA by 16% polyacrylamide gel electrophoresis at 1800 V 
for 2.5 h.  
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4.4.2. Maxam-Gilbert Sequencing Reaction65 
Ten µL of labeled DNA solution (~50000 cpm) was treated with 25 µL of formic 
acid and incubated at 25 °C for 4-5 min. The reaction was stopped by treatment with 200 
µL of 0.3 M sodium acetate, pH 7.0 mixed with 0.1 mM EDTA and 25 µg/mL tRNA. 
The resulting solution was containing 700 μL of ethanol and the DNA was precipitated. 
The DNA pellet was purified by ethanol precipitation and resuspended in 75 µL of 10% 
piperidine. The reaction mixture was incubated at 90 °C for 30 minutes, cooled down and 
the supernatant was removed under diminished pressure. The DNA pellet was washed 
and mixed with denaturing loading buffer containing 80% formamide, 2 mM EDTA, 1% 
bromophenol blue and 1% xylene cyanol, then heated at 90 °C for 10 min and stored in   ̶ 
20 °C. 
 
4.4.3. Electrophoretic Mobility Shift Assay 
The BCL2 i-motif and each of the mutants mentioned in Table 1 were [5-32P]-end 
labeled as noted above. These constructs were prepared in 50 mM Tris buffer with 100 
mM NaCl at pH 7.0. One µL (10000 cpm) of each of those DNAs were mixed with 10 
µM non-radioactive oligonucleotide counterparts. Ten pmol of each of those DNAs were 
then incubated with 2.5, 5, 7.5 on 10 pmol of RRM1 or RRM2 for 15 min at room 
temperature. The DNA ̶ protein mixtures were subjected to 12% non denaturing gel 
electrophoresis at 80 V for 1.5 h. The resulting bands were visualized using a 
phosphorimager. 
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4.4.4. Bromine FootPrinting Assay 
The bromine footprinting assay protocol was adapted from the previous 
procedure.106 BCL2 i-motif was [5-32P]-end labeled as described previously. Ten pmol of 
the purified DNA was incubated with bromine formed in situ by mixing a 50 mM 
solution of KBr and KHSO5 for 20 min at room temperature in a total volume of 20 µL. 
The reaction was terminated by the addition of  200 µL of 0.3 M sodium acetate 
containing 10 mg/mL calf thymus DNA  and 700 µL of cold ethanol. The reaction 
mixture was incubated in  ̶ 80 °C for 20 min and the DNA pellet was purified by 
additional ethanol purification steps. The DNA pellet was resuspended in 70 µL of 10% 
piperidine. The reaction mixture was incubated at 90 °C for 30 min, cooled and the 
supernatant was removed under diminished pressure. The DNA pellet was washed with 
water and mixed with denaturing loading buffer containing 80% formamide, 2 mM 
EDTA, 1% bromophenol blue and 1% xylene cyanol, then heated at 90 °C for 10 min and 
resolved in a denaturing polyacrylamide gel. 
 
4.4.5. Circular Dichroism  
CD experiments were performed based on the potocol described in literature.106 
The spectral data was collected using a Jasco-810 spectropolarimeter and a quartz cell of 
1.0 mm path length. Spectra were obtained at a scanning speed of 100 nm/min with a 
response time of 1 sec, over a wavelength range of 200-350 nm. For each scan, the data 
was recorded six times, avaraged, smoothed and baseline corrected to eliminate the signal 
contribution from buffer. The oligonucleotides were dissolved in 50 mM Tris buffer (pH 
6.6 and 7.0) containing 100 mM NaCl at a concentration of 5 µM. RRM1 and RRM2 
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were prepared in same buffer at 50 µM concentration. For binding interaction studies, CD 
spectra were obtained after incubating DNA and protein at room temperature for 15 min.  
 
4.4.6. Mutagenesis and Subcloning  
Three PCR (Polymerase Chain Reaction) site-directed mutagenesis procedure 
were carried out using NEB Q5 Mutagenesis kit. The forward and reverse primers for 
each PCR mutagenesis are listed in the Appendix.  NEB base changer web-tool was used 
to design the primers, in order to incorporate an amber codon (TAG) at either Y137 or 
Y104 and Y147. PCR reactions were performed in 25 L reaction mixtures, following 
the procedure described in the kit manual. Each reaction mixture contained 25 ng wild-
type template RRM1, encoded in a pET 28a vector, 125 ng of forward and reverse 
primers, 10 nmol of dNTPs, 2.5 units of DNA polymerase in 35 mM Tris-HCl at pH 8.0 
containing 12 mM potassium acetate, 5mM DTT and 0.05% Triton X-100 in 0.05 mM 
EDTA. A combination of the forward and reverse primers, 137-Forward and 137-Reverse 
or 104-Forward and 104-Reverse were used for the synthesis of RRM1-137TAG and 
RRM1-104TAG, respectively, whereas, 147-Forward and 147-Reverse were used for the 
synthesis of RRM1-147TAG. The products were ligated with the Q5 ligase master mix 
and transformed in DH5 E. coli cells. Purified plasmids were verified by sequencing. 
The product plasmids were the RRM1 constructs with a TAG codon at position 137 or 
104 and 147.  
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4.4.7. Competent Cell Preparation.    
A stock of DH5 competent cells was made for transformation, following the 
Invitrogen competent cell preparation protocol. The preparation was carefully done at  
 ̶ 4 °C in a sterile environment. A 250 mL LB culture produced a stock of 21.4 mL cells 
in 97 tubes of 220 uL aliquots. The transformation efficiency of the cells was 2.73X107 
when checked with pUC19 vectors. 
 
4.4.8. NVOC protected aminoacyl Dinucleotide Preparation. 
Crude aminoacylated pdCpA samples were dissolved in DMSO. The 
concentration of the resulting solution was checked by measuring the absorbance of the 
dinucleotide, at 260 nm wavelength and was found to be 96 ABS (absorbance unit). The 
pdCpA solutions were used for tRNA ligation to a final concentration of 5.0 ABS. 
 
4.4.9. Transcription of 74-Nucleotide tRNA and Purification 
The plasmid pYRNA8, which encodes a 74-nucleotide tRNA (tRNA-COH) was 
transformed into DH5 cells and a single colony was picked for overnight growth in 500 
mL LB media supplemented with 100 µg/mL ampicillin. The harvested cells were used 
for large-scale plasmid extraction following the Promega maxiprep-kit protocol. The 
Plasmid concentration was measured by checking the absorbance at 260 nm and a stock 
of 1 µg/mL solution was prepared by dissolving the plasmid in water. 
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4.4.10. Digestion of pYRNA8 Plasmid with FokI 
The pYRNA8 was completely linearized for the subsequent activity of the T7 
RNA polymerase. The plasmid was digested using FokI restriction endonuclease. The 
linear DNA was separated from protein impurities and purified by Phenol ̶ Chloroform 
extraction followed by ethanol precipitation. The digested product was run in a 1% 
agarose gel along with undigested plasmid as a control. The fastest migrating band was 
collected and purified. The DNA fragment containing 74-nucleotide tRNA, being 
expressed under a T7 promoter, was subjected to in vitro transcription. The conventional 
ampliscribe T7 transcription protocol was followed and based on previous data; a high 
yield of 74-nucleotide RNA was obtained with an additional use of 500 µg GMP in the 
transcription buffer. 
 
4.4.11. Purification of tRNA by DEAE Sephadex Chromatography 
After transcription, the reaction mixture was precipitated by the addition of 40 µL 
of 3M NaOAc at pH 5.0 and 1.3 mL of cold EtOH, then washed with 70% EtOH . The 
product was air dried and dissolved in 300 µL of 0.1 M NaOAc, pH 5.0. The solution was 
loaded onto 800 µL of Sephadex resin, equilibrated with the same buffer mentioned 
above and eluted with a step gradient of NaCl [0-0.9 M]. The fractions were purified and 
analyzed by electrophoresis on an 8% PAA ̶ Urea [polyacrylamide ̶ urea] gel at pH 8.4 
(TBE buffer) for 1h at 100 V. The tRNA was used in a ligation reaction with 
aminoacylated pdCpA in the presence of ATP and T4 RNA ligase.  
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4.4.12. Ligation of tRNA-COH with Aminoacyl-pdCpA and NVOC Deprotection 
Suppressor tRNA aminoacylation was carried out in 100 mL (total volume) of 
100 mM HEPES buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 
containing 2.0 mM ATP, 15 mM MgCl2, 100 μg of suppressor tRNA-COH, 5.0 A260 units 
of NVOC-protected 6-cyanotryptophanyl-pdCpA, 15% DMSO and 200 units of T4 RNA 
ligase. After incubation at 37 oC for 1 hour, the reaction was quenched by the addition of 
10 μL of 3 M NaOAc, pH 5.2, followed by 300 μL of ethanol. The reaction mixture was 
incubated at –20 oC for 30 minutes, then centrifuged at 15,000 × g at 4 oC for 30 minutes. 
The supernatant was carefully decanted and the tRNA pellet was washed with 100 μL of 
70% ethanol and dissolved in 30 μL of RNase free H2O. The NVOC-protected 6-
cyanotryptophanyl-tRNA was cooled to 2 oC and irradiated with a 500 W mercury-xenon 
lamp for 5 minutes. 
 
4.4.13. S-30 Preparation 
S-30 systems from E. coli BL-21 (DE-3) containing rrnB genes were prepared by 
procedure described in literature.118,119 Cells were grown at 31 °C in LB medium, 
supplemented with ampicillin (100g/L), until the optical density at 600 nm was 1.0. The 
cell solution was then diluted 10 times with LB medium and IPTG (500 g) and growth 
was continued until the optical density was 2.0. The cells were harvested and lysed by 
egg lysozyme (150 g/g of cells). Finally, the S-30 extract was dialyzed, aliquoted in 100 
L micro-centrifuge tubes and stored at -80 °C. 
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4.4.14. In vitro Protein Synthesis and Amber Suppression. 
Circular DNA plasmid containing the gene of interest can be transcribed and 
translated in one single reaction as long as the T7 polymerase is present. The 
transcription and translation reactions are done in one tube, i.e. termed as a “coupled” 
system.  The procedure is also referred to as “in vitro translation”.118 Reactions were 
carried out following a standard procedure developed in the Hecht Laboratory118 in 10 L 
reaction mixtures, with 600 ng plasmid containing the gene for the relevant protein, in 35 
mM Tris acetate, pH 7.4, 190 mM potassium glutamate, 30 mM ammonium acetate, 2 
mM DTT, 0.2 g/L aminoacyl tRNA, 3.5% polyethylene glycol (PEG)-6000, 20 g/L 
folinic acid, 20 mM ATP and GTP, 5 mM CTP and UTP, 100 mM mixture of amino 
acids, 0.1-0.4 l/L of S-30 preparation and 100 M (0.5 Ci/l) of  35S-methionine.  
In the suppression analysis with a plasmid containing a TAG codon, 
aminoacylated tRNAs were added to the reaction mixtue up to a concentration of 0.3 
g/L. Reactions were incubated at 37 °C for one hour. Purification of the protein was 
done following the Strep-Tactin manufacturer’s protocol (Iba-Lifesciences). Reaction 
yields were analyzed by visualizing the protein band in a 15% Tris-glycine SDS-PAGE 
gel and quantification of protein was done by imagephosphor software. In vivo protein 
expression was done by adding IPTG to an E. coli BL-21 (DE-3) cell culture after 3 
hours, containing RRM1, RRM2 or RRM3-4 plasmids. The cultures were incubated 
overnight at 37  °C, followed by the addition of rifampicin (1 µg/mL) and incubation for 
another 12-16 hours before lysing the cells by sonication. The separation of proteins from 
the cellular debris was performed by centrifugation at 4000 rpm. The supernatant was 
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filtered and loaded directly on a Strep-Tactin column. The protein was eluted with 50 
mM PBS buffer. 
 
4.4.15. FRET Experiment 
The FRET efficiency between donor and acceptor was measured in 
experimentally by gradual addition of DNA to 5 µM RRM1 solution at pH 4.5. The 
protein was incubated with the DNA for 5 min and then excited at 310 nm. Emission was 
measured immediately in the range of 325-550 nm. The emission profiles of the donors 
(RRM1-137-CTP, RRM1-104-CTP) and the donor ̶ acceptor complexes were normalized, 
integrated and fitted using the equation, E= IA/(IA+ID), where E is the FRET efficiency; IA 
and ID are the integrated intensities of the donor in unbound and bound forms, 
respectively. The distance between donor and acceptor was calculated by fitting FRET 
efficiency in the equation, R= R0*((1-E)/E)
1/6, where R0 is the Förster radius. R0 value 
was calculated by Poulami Talukder to be 26 Å using the method described in 
‘Introduction to Fluoroscence’ by David Jamesons.120 
 
4.4.16. Graphical Modeling and Simulation of DNA ̶ Protein Interaction 
RRM1 was modeled based on homology modeling using Modeller.121,122 The 
fluorescence data was individually baseline corrected, normalized, integrated and used 
for FRET efficiency calculations using statistical data processing software, Origin 8. The 
FRET efficiency and distances between donors and acceptor were calculated using the 
method described in the previous section. A pdb file for the 39-nucleotide long i-motif 
was generated using the Make-NA algorithm.123 The DNA binding residues in RRM1 
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were found using DP-bind web-tool.124,125 The predicted active residues were R105, 
G106, F134, K135, R136, Q137, Q165, F168, N170, Y171. Based on the current study 
and the previously reported results,113 the active residues of i-motif were found to be in 
loop L1 and L3 (lateral loops). The binding pockets on RRM1 were scanned by 
Patchdock web-tool for favorable binding interactions,126,127 which is followed by the 
rigid body docking, using Hex-docking algorithm.128,129 The data was confirmed by the 
Haddock docking algorithm (Figure 4.20 A), using active residues as ‘ambiguous-binding 
restraints’.114-116 Furthermore, the dynamic docking was performed using Haddock expert 
interface (~24 hours processing time for each pair), considering flexible regions of 
protein and DNA, solvent factors, polar-nonpolar interactions, energy minimization, 
hydrogen bonding and backbone conformational restraints. The FRET experiment 
derived data was used as unambiguous restraints for dynamic modeling (Figure 4.20B). 
The represented data was the best model from a library of over 1000 virtual modeling 
results. The molecules were visualized and virtual mutations were done using PyMol130 
software. 
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APPENDIX A 
 
DNA AND PROTEIN SEQUENCES OF THE RRM CONSTRUCTS  
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A.1. hnRNP LL isoform_1 (NP_612403)  
 
 1   msssssspre tyeedreyes qakrlkteeg eidysaeege nrreatprgg gdgggggrsf 
 61  sqpeaggshh kvsvspvvhv rglcesvvea dlvealekfg ticyvmmmpf krqalvefen 
 121 idsakecvtf aadepvyiag qqaffnysts kritrpgntd dpsggnkvll lsiqnplypi 
 181 tvdvlytvcn pvgkvqrivi fkrngiqamv efesvlcaqk akaalngadi yagcctlkie 
 241 yarptrlnvi rndndswdyt kpylgrrdrg kgrqrqailg ehpssfrhdg ygshgpllpl 
 301 psryrmgsrd tpelvayplp qasssymhgg npsgsvvmvs glhqlkmncs rvfnlfclyg 
 361 niekvkfmkt ipgtalvemg deyaveravt hlnnvklfgk rlnvcvskqh svvpsqifel 
 421 edgtssykdf amsknnrfts agqaskniiq ppscvlhyyn vplcvteetf tklcndhevl 
 481 tfikykvfda kpsaktlsgl lewecktdav ealtalnhyq irvpngsnpy tlklcfstss 
 541 hl 
 
Red amino acids indicate RRM1 
Blue amino acids indicate RRM2 
Green amino acids indicate RRM3 
Purple amino acids indicate RRM4 
 
 
 
A.2. Constructs used in this study 
Each of the constructs had an NcoI site (CCATGG) at the 5-end, with an embedded 
transcription start site (ATG) followed by a fused glycine sequence (GGT) from the 
original reading frame of the RRM domains. The constructs are attached to a 24 
nucleotide long Strep-tag sequence (Yellow bases) followed by a stop codon (TAA) at 
the 3-end. 
 
 
A.2.1. RRM1 gene sequence 
 
5’--CCATG   
 
GGTCGTTCTTTCTCTCAGCCGGAAGCGGGTGGTTCTCACCACAAAGTTTCTGTTTCTCC 
 
GGTTGTTCACGTTCGTGGTCTGTGCGAATCTGTTGTTGAAGCGGACCTGGTTGAAGCGC 
 
TGGAAAAATTCGGTACCATCTGCTACGTTATGATGATGCCGTTCAAACGTCAGGCGCTG 
 
GTTGAATTCGAAAACATCGACTCTGCGAAAGAATGCGTTACCTTCGCGGCGGACGAACC 
 
GGTTTACATCGCGGGTCAGCAGGCGTTCTTCAACTACTCTACCTCTAAACGTATCACCC 
 
 126 
GTCCGGGTAACACCGACGACCCGTCTGGTGGT TGGTCTCACCCGCAGTTCGAAAAA  
 
TAA—3’ 
 
 
A.2.2. RRM1 amino acid sequence (13 kDa) 
 
MGRSFSQPEAGGSHHKVSVSPVVHVRGLCESVVEADLVEALEKFGTICYVMMMPFKRQA 
 
LVEFENIDSAKECVTFAADEPVYIAGQQAFFNYSTSKRITRPGNTDDPSGG  
 
WSHPQFEK* 
 
 
A.2.3. RRM1 coding region in pET 28a vector 
 
3     ATG GGT CGT TCT TTC TCT CAG CCG GAA GCG GGT GGT TCT CAC CAC   47 
1     Met Gly Arg Ser Phe Ser Gln Pro Glu Ala Gly Gly Ser His His   15 
 
48    AAA GTT TCT GTT TCT CCG GTT GTT CAC GTT CGT GGT CTG TGC GAA   92 
16    Lys Val Ser Val Ser Pro Val Val His Val Arg Gly Leu Cys Glu   30 
 
93    TCT GTT GTT GAA GCG GAC CTG GTT GAA GCG CTG GAA AAA TTC GGT   137 
31    Ser Val Val Glu Ala Asp Leu Val Glu Ala Leu Glu Lys Phe Gly   45 
 
138   ACC ATC TGC TAC GTT ATG ATG ATG CCG TTC AAA CGT CAG GCG CTG   182 
46    Thr Ile Cys Tyr Val Met Met Met Pro Phe Lys Arg Gln Ala Leu   60 
 
183   GTT GAA TTC GAA AAC ATC GAC TCT GCG AAA GAA TGC GTT ACC TTC   227 
61    Val Glu Phe Glu Asn Ile Asp Ser Ala Lys Glu Cys Val Thr Phe   75 
 
228   GCG GCG GAC GAA CCG GTT TAC ATC GCG GGT CAG CAG GCG TTC TTC   272 
76    Ala Ala Asp Glu Pro Val Tyr Ile Ala Gly Gln Gln Ala Phe Phe   90 
 
273   AAC TAC TCT ACC TCT AAA CGT ATC ACC CGT CCG GGT AAC ACC GAC   317 
91    Asn Tyr Ser Thr Ser Lys Arg Ile Thr Arg Pro Gly Asn Thr Asp   105 
 
318   GAC CCG TCT GGT GGT TGG TCT CAC CCG CAG TTC GAA AAA TAA ---   362 
106   Asp Pro Ser Gly Gly Trp Ser His Pro Gln Phe Glu Lys End XXX   119 
 
 
A.2.4. RRM2 gene sequence 
 
5’--CCATG   
 
GGTAACACCGACGACCCGTCTGGTGGTAACAAAGTTCTGCTGCTGTCTATCCAGAACCC 
 
GCTGTACCCGATCACCGTTGACGTTCTGTACACCGTTTGCAACCCGGTTGGTAAAGTTC 
 
AGCGTATCGTTATCTTCAAACGTAACGGTATCCAGGCGATGGTTGAATTCGAATCTGTT 
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CTGTGCGCGCAGAAAGCGAAAGCGGCGCTGAACGGTGCGGACATCTACGCGGGTTGCTG 
 
CACCCTGAAAATCGAATACGCGCGTCCGACCCGTCTGAACGTTATCCGTAACGACAACG 
 
ACTCTTGGGACTACACCAAACCGTACCTGGGTCGTCGTGACCGTGGTAAAGGT  
 
TGGTCTCACCCGCAGTTCGAAAAA TAA—3’ 
 
 
A.2.5. RRM2 amino acid sequence (16 kDa) 
 
MGNTDDPSGGNKVLLLSIQNPLYPITVDVLYTVCNPVGKVQRIVIFKRNGIQAMVEFES 
 
VLCAQKAKAALNGADIYAGCCTLKIEYARPTRLNVIRNDNDSWDYTKPYLGRRDRGKG     
 
WSHPQFEK* 
 
 
A.2.6. RRM2 coding region in pET 28a vector. 
 
3     ATG GGT AAC ACC GAC GAC CCG TCT GGT GGT AAC AAA GTT CTG CTG   47 
1     Met Gly Asn Thr Asp Asp Pro Ser Gly Gly Asn Lys Val Leu Leu   15 
 
48    CTG TCT ATC CAG AAC CCG CTG TAC CCG ATC ACC GTT GAC GTT CTG   92 
16    Leu Ser Ile Gln Asn Pro Leu Tyr Pro Ile Thr Val Asp Val Leu   30 
 
93    TAC ACC GTT TGC AAC CCG GTT GGT AAA GTT CAG CGT ATC GTT ATC   137 
31    Tyr Thr Val Cys Asn Pro Val Gly Lys Val Gln Arg Ile Val Ile   45 
 
138   TTC AAA CGT AAC GGT ATC CAG GCG ATG GTT GAA TTC GAA TCT GTT   182 
46    Phe Lys Arg Asn Gly Ile Gln Ala Met Val Glu Phe Glu Ser Val   60 
 
183   CTG TGC GCG CAG AAA GCG AAA GCG GCG CTG AAC GGT GCG GAC ATC   227 
61    Leu Cys Ala Gln Lys Ala Lys Ala Ala Leu Asn Gly Ala Asp Ile   75 
 
228   TAC GCG GGT TGC TGC ACC CTG AAA ATC GAA TAC GCG CGT CCG ACC   272 
76    Tyr Ala Gly Cys Cys Thr Leu Lys Ile Glu Tyr Ala Arg Pro Thr   90 
 
273   CGT CTG AAC GTT ATC CGT AAC GAC AAC GAC TCT TGG GAC TAC ACC   317 
91    Arg Leu Asn Val Ile Arg Asn Asp Asn Asp Ser Trp Asp Tyr Thr   105 
 
318   AAA CCG TAC CTG GGT CGT CGT GAC CGT GGT AAA GGT TGG TCT CAC   362 
106   Lys Pro Tyr Leu Gly Arg Arg Asp Arg Gly Lys Gly Trp Ser His   120 
 
363   CCG CAG TTC GAA AAA TAA ---   383 
121   Pro Gln Phe Glu Lys End XXX   126 
 
 
A.2.7. RRM3-4 gene sequence  
 
5’--CCATG  
 
 128 
GGTGGTAACCCGTCTGGTTCTGTTGTTATGGTTTCTGGTCTGCACCAGCTGAAAATGAA 
 
CTGCTCTCGTGTTTTCAACCTGTTCTGCCTGTACGGTAACATCGAAAAAGTTAAATTCA 
 
TGAAAACCATCCCGGGTACCGCGCTGGTTGAAATGGGTGACGAATACGCGGTTGAACGT 
 
GCGGTTACCCACCTGAACAACGTTAAACTGTTCGGTAAACGTCTGAACGTTTGCGTTTC 
 
TAAACAGCACTCTGTTGTTCCGTCTCAGATCTTCGAACTGGAAGACGGTACCTCTTCTT 
 
ACAAAGACTTCGCGATGTCTAAAAACAACCGTTTCACCTCTGCGGGTCAGGCGTCTAAA 
 
AACATCATCCAGCCGCCGTCTTGCGTTCTGCACTACTACAACGTTCCGCTGTGCGTTAC 
 
CGAAGAAACCTTCACCAAACTGTGCAACGACCACGAAGTTCTGACCTTCATCAAATACA 
 
AAGTTTTCGACGCGAAACCGTCTGCGAAAACCCTGTCTGGTCTGCTGGAATGGGAATGC 
 
AAAACCGACGCGGTTGAAGCGCTGACCGCGCTGAACCACTACCAGATCCGTGTTCCGAA 
 
CGGTTCTAACCCGTACACCCTGAAACTGTGCTTCTCTACCTCTTCTCACCTG  
 
TGGTCTCACCCGCAGTTCGAAAAA TAA—3’ 
 
 
A.2.8. RRM3-4 amino acid sequence (24 kDa) 
 
MGGNPSGSVVMVSGLHQLKMNCSRVFNLFCLYGNIEKVKFMKTIPGTALVEMGDEYAVE 
 
RAVTHLNNVKLFGKRLNVCVSKQHSVVPSQIFELEDGTSSYKDFAMSKNNRFTSAGQAS 
 
KNIIQPPSCVLHYYNVPLCVTEETFTKLCNDHEVLTFIKYKVFDAKPSAKTLSGLLEWE 
 
CKTDAVEALTALNHYQIRVPNGSNPYTLKLCFSTSSHL 
 
WSHPQFEK* 
 
 
 
 
 
A.2.9. RRM3-4 coding region in pET 28a vector. 
 
3     ATG GGT GGT AAC CCG TCT GGT TCT GTT GTT ATG GTT TCT GGT CTG   47 
1     Met Gly Gly Asn Pro Ser Gly Ser Val Val Met Val Ser Gly Leu   15 
 
48    CAC CAG CTG AAA ATG AAC TGC TCT CGT GTT TTC AAC CTG TTC TGC   92 
16    His Gln Leu Lys Met Asn Cys Ser Arg Val Phe Asn Leu Phe Cys   30 
 129 
 
93    CTG TAC GGT AAC ATC GAA AAA GTT AAA TTC ATG AAA ACC ATC CCG   137 
31    Leu Tyr Gly Asn Ile Glu Lys Val Lys Phe Met Lys Thr Ile Pro   45 
 
138   GGT ACC GCG CTG GTT GAA ATG GGT GAC GAA TAC GCG GTT GAA CGT   182 
46    Gly Thr Ala Leu Val Glu Met Gly Asp Glu Tyr Ala Val Glu Arg   60 
 
183   GCG GTT ACC CAC CTG AAC AAC GTT AAA CTG TTC GGT AAA CGT CTG   227 
61    Ala Val Thr His Leu Asn Asn Val Lys Leu Phe Gly Lys Arg Leu   75 
 
228   AAC GTT TGC GTT TCT AAA CAG CAC TCT GTT GTT CCG TCT CAG ATC   272 
76    Asn Val Cys Val Ser Lys Gln His Ser Val Val Pro Ser Gln Ile   90 
 
273   TTC GAA CTG GAA GAC GGT ACC TCT TCT TAC AAA GAC TTC GCG ATG   317 
91    Phe Glu Leu Glu Asp Gly Thr Ser Ser Tyr Lys Asp Phe Ala Met   105 
 
318   TCT AAA AAC AAC CGT TTC ACC TCT GCG GGT CAG GCG TCT AAA AAC   362 
106   Ser Lys Asn Asn Arg Phe Thr Ser Ala Gly Gln Ala Ser Lys Asn   120 
 
363   ATC ATC CAG CCG CCG TCT TGC GTT CTG CAC TAC TAC AAC GTT CCG   407 
121   Ile Ile Gln Pro Pro Ser Cys Val Leu His Tyr Tyr Asn Val Pro   135 
 
408   CTG TGC GTT ACC GAA GAA ACC TTC ACC AAA CTG TGC AAC GAC CAC   452 
136   Leu Cys Val Thr Glu Glu Thr Phe Thr Lys Leu Cys Asn Asp His   150 
 
453   GAA GTT CTG ACC TTC ATC AAA TAC AAA GTT TTC GAC GCG AAA CCG   497 
151   Glu Val Leu Thr Phe Ile Lys Tyr Lys Val Phe Asp Ala Lys Pro   165 
 
498   TCT GCG AAA ACC CTG TCT GGT CTG CTG GAA TGG GAA TGC AAA ACC   542 
166   Ser Ala Lys Thr Leu Ser Gly Leu Leu Glu Trp Glu Cys Lys Thr   180 
 
543   GAC GCG GTT GAA GCG CTG ACC GCG CTG AAC CAC TAC CAG ATC CGT   587 
181   Asp Ala Val Glu Ala Leu Thr Ala Leu Asn His Tyr Gln Ile Arg   195 
 
588   GTT CCG AAC GGT TCT AAC CCG TAC ACC CTG AAA CTG TGC TTC TCT   632 
196   Val Pro Asn Gly Ser Asn Pro Tyr Thr Leu Lys Leu Cys Phe Ser   210 
 
633   ACC TCT TCT CAC CTG TGG TCT CAC CCG CAG TTC GAA AAA TAA ---   677 
211   Thr Ser Ser His Leu Trp Ser His Pro Gln Phe Glu Lys End XXX   224 
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APPENDIX B 
 
LIST OF PRIMERS FOR RRM1 MUTAGENESIS 
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B.1. RRM1 mutagenesis primers 
mutagenesis primer Sequence (5-3) 
137-Forward AACCGGTTTAgATCGCGGGTC 
137-Reverse 
 
CGTCCGCCGCGAAGGTAA 
 
104-Forward CCATCTGCTAgGTTATGATGATG 
104-Reverse 
 
TACCGAATTTTTCCAGCG 
 
147-Forward TCTTCAACTAgTCTACCTCTAAACGTATCACCCG 
147-Reverse 
 
ACGCCTGCTGACCCGCGA 
 
 
 
 
 
 
 
 
 
 
 
 
